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 The simplest cyclic peptide is composed of two amino acids and forms a 2,5-
diketopiperazine (DKP). Diketopiperazine containing natural products can be found 
from eukaryotic, fungal, and bacterial sources and are present in a diverse array of 
scaffolds. DKPs are most commonly biosynthesized by non-ribosomal peptide 
synthetases (NRPS) modules condensing two amino acids into a DKP upon 
offloading by a thioesterase. Recently a new class of enzymes, cyclodipeptide 
synthases (CDPS) have been identified as capable of synthesizing DKPs from tRNA 
charged amino acid precursors. Since this discovery, there has been a dramatic rise 
in the identification and characterization of CDPS containing gene clusters, and 
some classic natural products have been ascribed to these clusters, including 
albonoursin and bicyclomycin. 
 The subject of this thesis is the study of a cyclodipeptide synthase containing 
gene clusters which also harbor a cytochrome P450 which oxidatively dimerizes 
DKP monomers into topologically complex dimers with exquisite selectivity. These 
enzymes catalyze a C–H functionalization reaction and transform an sp2 hybridized 
C–H bond into a C–C or C–N bond. We discovered a series of unique cytochromes, 
NznB, NascB, and homologues NascB-S1868, and NascB-F5053 all of which 
catalyze reactions novel site- stereo- and chemoselectivity. Chapter 1 discusses the 
synthetic and biosynthetic literature regarding diketopiperazine dimers. In the 
Chapters 2 and 3, these cytochromes are characterized biochemically using native 
and non-native substrates in in vitro and in vivo biocatalytic reactions demonstrating 
their synthetic utility, and Chapter 4 interrogates the structure and mechanism of the 
dimerization reaction of NascB-F5053. Chapter 5 discusses the future directions and 





1.1 Diketopiperazine Dimers: History, Isolation and Biosynthetic Hypotheses 
In the effort to discover of new molecules to inhibit bacterial growth, in 1944 
Selman Waksman and Elizabeth Bugie and isolated a compound, (+)–chaetomin 
(named for the Chaetomium cochliodes)1-2, with antibiotic activity similar to that of 
penicillin against a spectrum of gram-positive pathogenic bacteria including 
Staphylococcus aureus. The structure of chaetomin went unknown for over 30 years, 
despite the reconfirmation of its antibacterial activity as well as discovery of its ability to 
inhibit viral ribonucleic acid synthesis in vivo in a number of cell lines.3 Elemental 
analysis and NMR spectroscopy lead to the initially proposed structure 1 from Safe and 
Taylor3 in 1972, which was later corrected by McInnes, Taylor, Walter in 1976 to 2 
through a series of shrewd 15N NMR experiments using 15N-enriched chaetomin 
isolated from feeding studies using Na15NO3.4 Two years prior, the first structures of 
symmetrical dimeric epidithiodiketopiperazines (ETPs) (+)-chaetocin and (+)-verticillin 
were solved by Hauser5 and Katagiri6 who also reported antibiotic, and anti-cancer 
activities. Based on the structure of these compounds, as well as incorporation of 
radiolabelled amino acid precursors in the investigation of the biosynthesis of 
monomeric ETP, gliotoxin, these groups hypothesized that monomeric precursors of 
these dimers arise via the condensation of two amino acids into DKP monomers. They 
postulated that similar to the biosynthetic proposal put forth by Woodward7 and 
Robinson8 for the related polypyrroloindoline natural products, that these monomers 
undergo a single electron oxidation-dimerization cascade to give rise to the dimeric 




Figure 1-1. A) Initially proposed structure of (+)-chaetomin (1), corrected structure of (+)-chaetomin (2), and (+)-
verticillin (3). B) Incorporation of radiolabelled intermediates in the biosynthesis of gliotoxin (4). C) biosynthetic 
proposal of Woodward and Robinson.9 
 
Since these seminal reports, the isolation of diketopiperazine dimers (DKPs) with 
a broad range of biological activites have been reported, including but not limited to 
antibacterial, anticancer, antiviral, antiparasitic, antifungal, antimalarial, 
immunosuppressive, immunomodulatory, phytotoxic, nematicidial and antiplatelet 
effects10. The broad range of biological activities as well as well as curiosity surrounding 

















































































A) First structures solved of dimeric DKP natural products
B) Incorporation of radiolabelled biosynthetic precursors into gliotoxin scaffold
= radiolabelled atoms





























diverse family11, along with investigations into their access via total synthesis and as 
well as preliminary investigations into their biosynthesis. 
 
1.2 Structural Diversity and Total Synthesis of Diketopiperazine Dimers And Their 
Putative Biosynthetic Congeners 
The dimeric DKP natural products are composed of a wide variety of 
proteinogenic amino acids, possess a variety of oxidation states at both carbon and 
sulfur, (R)- and (S)- configurations at their axis of dimerization, and multiple 
connectivities between the two monomers (Figure 1-2). Given this multiplicity in 
constitutional variables, there are no general classes of DKP dimers. We chose to 
classify these compounds by their differences in connectivity; as the selectively in the 
biosynthetic dimerization of these compounds is unknown and likely represents a point 
of biosynthetic divergence.  
Similarly, each connectivity also represents a point of synthetic divergence, as 
access to each connectivity is accompanied with a unique synthetic challenge. As such, 
a variety of elegant synthetic methods towards the total synthesis of these compounds 
have been developed in order to overcome each of these unique challenges. To 
exemplify both the variety of connectivities native to DKP dimers as well as the diversity 
of synthetic methods to assemble these compounds, representative examples from 
each connectivity (enumerated based on indole numbering) have been selected to 
display the history and variety of approaches to access these compounds. While a 
variety of non-indole linked dimers are also known (Figure 1-3, 15-19), these 






Figure 1-2. Representative dimers for all known tryptophan-tryptophan linked connectivities, including non-cyclized 





































































































































Figure 1-3. Representative examples of non-tryptophan linked DKP dimers. Notably all of these compounds have 
eluded total synthesis.17-21 
 
1.3 Representative Total Syntheses of C3-C3’ Linked Diketopiperazine Dimers 
Biomimetic syntheses take inspiration from Nature’s method of assembly of 
molecules to develop synthetic methods to perform a similar bond disconnection. The 
C3-C3’ alkaloids are particularly well suited to biomimetic synthesis two simple building 
blocks can be oxidatively dimerized to assemble these symmetrical dimers, as shown 
by Hino an coworkers in their pioneering synthesis of (±)-folicanthine.22 Based on the 
biosynthetic hypothesis put forth by Woodward7 and Robinson8 (Figure 1-4), Hino et. al. 
utilized a photooxidative dimerization  to the total synthesis of (±)-folicanthine (22) from 












































































Figure 1-4. Biomimetic total synthesis of (±)-folicanthine via photooxidation.22 
 
Given the shared skeleton between (±)-folicanthine and 25, they attempted the 
same oxidative strategy. However, this resulted in oxidative cyclization of 
diketopiperazine precursor 23 rather than dimerization, giving hydroxypyrroloindole 24, 
as the major product in 20% yield as a mixture of diastereomers. After screening a 
variety of oxidants, it was found the thallium (III) trifluoroacetate was successful in 
dimerizing 23 into desired product 25, albeit in a modest 3% yield. Despite the low yield 
of the dimerization, this pioneering synthesis demonstrated the value of pursuing 
biomimetic approaches to symmetrical DKP dimers.23 
 
 
Figure 1-5. Biomimetic synthesis of (–)-ditryptophenaline via TTFA oxidation. 
 
Movassaghi and coworkers further exemplified the value of biomimetic synthetic 
methodology in their stereospecific total synthesis of (+)-WIN 64821 and (–)-







































































near (1:1) mixture of exo- and endo- cyclized tertiary bromides 27 and 28 respectively. 
After methylation of 28 to give 29, these two monomers were carried forward in parallel 
and under cobalt-mediated solvent caged reductive coupling conditions similar to those 
developed by Baldwin et. al. in their synthesis of (+)-biatractylolide24-25, 27 and 29 were 
dimerized into symmetrical dimers 30 and 31 respectively, which were then deprotected 
to give 25 and 32. The parallel nature of this synthesis takes advantage of the (1:1) 
diastereoselectivity of bromocyclization access both natural products, and pseudo-
diastereomers 25 and 32. While this strategy is extremely efficient, the outcome is 
substrate-controlled, as the configuration of the tertiary bromide sets the 
stereochemistry of the dimerization.26 
 
 
Figure 1-6. Movassaghi’s bioinspired parallel total synthesis of 25 and 32 via solvent caged reductive radical 









































































































































Further building on the biomimetic approach, Xia et. al developed a copper 
catalyzed oxidative cyclization/dimerization reaction to forge the dimeric structure of 32 
and 25 (Figure 1-7). While this approach is again extremely efficient, it requires the use 
of a protecting group for the indole nitrogen, and as such the starting material is a 
protected tryptophan, rather than the diketopiperazine itself, and as such the 
diketopiperazine must be formed after dimerization. And although also sets the 
dimerization stereochemistry as well as forms the dimeric scaffold all at once, the 
reaction is again under substrate control, as selection of protecting group of the indole 
nitrogen steers the stereochemistry of the cyclization cascade.27 
 
Figure 1-7. Xia’s biomimetic total synthesis of 32 and 25 via copper-catalyzed oxidative dimerization of protected 
tryptophans.27 
 
1.4 Representative Total Syntheses of C3-N1’ Linked Diketopiperazine Dimers 
While there have been biomimetic approaches the C3-N1’ connectivity, they are 
based on methodology developed for the C3-C6’ connectivity and will be discussed in 
that section. Rather, the approaches for the Liao et. al. utilized in the total synthesis of 
C3-N1’ linked dimer, pestalazine C (44),28  employed a chiral phosphoric acid (46) to set 
the stereochemistry of the dimerization in the the C–N bond forming reaction (Figure 1-
8). Diketopiperazine 40 was subjected to the optimized azo-coupling conditions with 
chiral phosphoric acid 46, which gave azo-compound 41 in greater than 20:1 d.r. in 79% 
yield. The N–N bond was reductively cleaved in good yield to give amine 42. 42 was 






































































scaffold was completed as the second DKP core was appended via Pd-catalyzed 
Larock annulation with alkyne 47, as seen in the synthesis of C3-C6’ linked dimers (+)-
naseseazines A as well as the synthesis of C6-N1’ dimer (–)-aspergilazine A (13) by 
Reisman et. al.29 
 
 
Figure 1-8. Liao’s total synthesis of (+)-pestalazine B via azo-coupling, amination, and indole synthesis.28 
 
Highlights of this synthesis include the development and utilization of robust 
chemistry which requires no protecting group manipulations of the reactive amine and 
amide functional groups, and generation of the C–N dimerization axis in high 
diastereoselectivity. However, this methodology is exclusively applicable to the 
formation of C–N bond-linked DKP dimers, and as the northern tryptophan indole is 
synthesized at a late stage via alkynyl DKP 47, cannot take advantage of low-cost, and 
commercially available protected proteinogenic amino acids as chiral pool starting 
materials. Biomimetic syntheses that utilize commercially available amino acids as 
starting materials to construct the diketopiperazine and form the C–N bond at a late-
stage are known30. However these syntheses require protecting and steering groups to 




































































































1.5 Representative Total Synthesis of C3-C7’ Linked Diketopiperazine Dimers 
The recent development of cross-coupling methodology to forge sp3-sp2 carbon-




Figure 1-9. Collective total synthesis of C3-C7’ linked dimers 53, 10 and 54, by Gong et. al. 31 
 
The route developed by Gong et. al. (Figure 1-9) is extremely efficient, as it takes 
advantage of amino acid chiral pool starting materials, and utilizes contemporary C–H 
functionalization methods to install the C7 boronic ester, and nickel-catalyzed sp2-sp3 
bond cross-electrophile coupling to generate the C3-C7’dimeric axis.31 However, similar 
to other dimerization methods, the stereochemistry of the dimerization is set early in the 
halocyclization and resulting stereochemistry of tertiary chloride 51. Starting from amino 
acid derivatives 48 and 51, allows for diversification of dimeric core 52, however this 
strategy requires the use of multiple orthogonal protecting groups, and cannot be 
employed in dimerizing diketopiperazines directly. Biomimetic approaches which directly 
couple diketopiperazines and form the C3-C7’ carbon-carbon bond at a late stage are 
known,32 however these syntheses also suffer from the use of protecting groups and the 
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1.6 Representative Total Syntheses of C3-C6’ Linked Diketopiperazine Dimers 
The (+)-naseseazines A (11) and B (48) are the first diketopiperazine dimers 
isolated from bacterial sources.15 In their retrobiosynthetic analysis, Movassaghi et. al 
proposed that these monomers are likely assembled via nucleophilic addition to an 
enzymatically generated carbocation (Figure 1-10).33 
 
Figure 1-10. Possible mechanisms of biosynthetic dimerization described by Movassaghi et. al.33 
 
To mimic this proposed biosynthetic hypothesis, access these non-symmetrical 
dimers, Movassaghi et. al. developed a convergent approach using a silver-mediated 
ionization of Cbz-protected tertiary bromide 55 in the presence of Cbz- protected 
diketopiperazine 54, resulting in a near 1:1 mixture of constitutional isomers 56 and 57 
in 53% yield. 56 and 57 could be deprotected to give (+)-naseseazine B (58) as well as 
(+)-iso-naseseazine B (59). This synthesis was applied to heterodimer (+)-naseseazine 


















































































































Figure 1-11. First generation biomimetic synthesis of (+)-naseseazine B (58) and (+)-iso-naseseazine B (59)33 
 
To improve the selectivity site-selectivity, a second generation synthesis 
employed electrofugal trifluoroborate 60, to build up charge density at the desired 
nucleophilic carbon to direct C–C bond formation. This resulted in complete control of 
site selectivity during dimerization (50% yield), and dimers could again be deprotected 
to give desired natural products 58 and 11 (Figure 1-12). 
 
 
Figure 1-12. Second-generation, site-selective biomimetic syntheses of (+)-naseseazines A (11) and B (58).33 
 
The use of trifluoroborates to direct C–C bond formation enabled complete 
selectivity in the dimerization reaction. However, this strategy requires pre-
functionalization of a single monomer which then predetermines the connectivity of 
dimerization, and as in previous syntheses the stereochemistry of dimerization is preset 

















































R = Cbz (57)




R = Cbz (56)







































































Figure 1-13. Biomimetic synthesis of C3-C7’ (+)-asperazine (53), (+)-iso-pestalazine A (64) (+)-pestalazine A (10), 
and C3-N1’ linked (+)-asperazine A (9) and (+)-pestalazine B (44) by Movassaghi et. al.30, 32 
 
As referenced, this biomimetic Friedel-Crafts approach was also utilized in the 
synthesis of unsymmetrical dimers C3-C7’ linked (+)-asperazine (53), (+)-iso-
pestalazine A (64), and (+)-pestalazine A (10) and C3-N1’ and (+)-asperazine A (9) and 
(+)-pestalazine B (44) (Figure 1-13). However, the use of trifluoroborates did not prove 
to be a general strategy for guiding bond formation, and the transient use of blocking 
and steering functionalities were required for selective bond formation. Transiently 
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as in the synthesis of the (+)-naseseazines, the configuration of dimerization was set by 
stereochemistry of tertiary bromide 60.  
 
1.7 Total Syntheses of C6-N1’ Linked Diketopiperazine Dimer, (–)-Aspergilazine A 
(13) 
Unique among indole linked DKP dimers, (–)-aspergilazine A (13) is unique as 
neither monomer is cyclized, and the axis of dimerization is at two sp2 hybridized atoms 
(C6–N1’). Reisman et. al. were able to rapidly assemble this dimer via leveraging the 
innate pseudo-symmetry of this homodimer, and a utilization of a single 
diketopiperazine precursor (68) (Figure 1-14)29. Selective Pd-catalyzed amination of 2-
bromoiodobenzene 65, with bromoaniline 66, gave diarylamine 67. Larock indole 
synthesis utilized with 3 equivalents of 68, and in situ desilation post annulation gave (–
)-aspergilazine A (13) in 45% over two steps.  
 
 
Figure 1-14. Total synthesis of (–)-aspergilazine A via selective amination and Larock annulation to install both DKP 
cores by Reisman et. al.29 
 
1.8 Total Synthesis of Putative Oxidatively-Tailored Indole Linked Dimer (+)-
gliocladin C (77) 
In the isolation of C3-C3’ linked, C2-symmetrical dimers such as the (+)-
verticillins ((+)-verticillin, 3) and (+)-leptosins, structurally similar molecules such as 
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strong base, generates 68 in an unspecified yield. This led to the hypothesis that 3 and 
68 may be biosynthetically related, and 3 may be generated via a retro-aldol type 
reaction, cleaving off a diketopiperazine core and re-aromatizing the northern indole 
(Figure 1-15, A). Recently an example of a retro-aldol reaction in the biosynthesis of 
diketopiperazine-containing fungal metabolite, aspirochlorine (72) has been 
demonstrated, lending credence to this biosynthetic proposal (Figure 1-15, B).35-36 
 
 
Figure 1-15. A) Chemical degradation of 3 to 68, suggesting the biosynthetic relationship between these two co-
isolates, B) Recently discovered retro-aldol in biosynthesis of fungal metabolite aspirochlorine (72). 34 
 
Stephenson et. al. used visible light photocatalysis to assemble the core 
structure of related compound, (+)-gliocladin C (77) in a biomimetic radical arylation.37 
Boc-protection and bromocyclization of protected tryptophan 73, gave tertiary bromide 
74 in 91% yield. After amide formation with methylamine (87% yield), under conditions 
developed for radical dehalogenation and arylation of alkyl halides,38 75 was coupled to 
indole-2-carboxaldehyde in high yield (82%). This core structure was then further 








































































R = H (71)




A) Putative biogenesis of gliocladines from verticillins
B) Biosynthetic retro-aldol in aspirochlorine biosynthesis
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Figure 1-16. Total synthesis of (+)-gliocladin C (77) enabled by photoredox catalysis by Stephenson et. al.37 
 
1.9 Investigations In Fungal Biosynthesis of DKP Dimers 
In 2013, Walsh et. al. published the first report disclosing the biosynthetic gene 
cluster for unsymmetrical ETP dimer (+)-chaetocin.39 Genetic disruption and 
accumulation of intermediates in the gliotoxin biosynthetic pathway identified key genes 
implicated in the assembly of the DKP core (GliP, non-ribosomal peptide synthetase 
(NRPS)).40 Genome assembly from Illumina sequencing of total nucleic acids isolated 
from (+)-chaetocin producer, Chaetomium virescens (ATCC 26417), was queried using 
GliP as a probe gene to identify putative (+)-chaetocin biosynthetic gene clusters. This 
resulted in discovery of putative NRPS, ChaP and primers were designed to screen a 
cosmid library prepared from C. viriscens genomic DNA, and lead to the identification of 
a 38 kb cluster of 14 genes putatively involved in (+)-chaetocin biosynthesis (Table 1-1).  
 
Gene Accession # of closest homologue Proposed function Similarity (E value) 
chaM XM_001258084 methyltransferase 6 X 10
 -118 
chaE XM_001933514  cytochrome P450 ; dimerization  6 X 10
 -72 
chaT XM_001226009 thioredoxin reductase ; dithiol formation 3 X 10
 -91 
chaZ XM_002375564 regulation of chaetocin gene cluster expression 9 X 10
 -13 
chaB XM_002842656 cytochrome P450 ; pyrroloindole formation  2 X 10
 -40 
chaA XM_003066250 ABC transporter ; chaetocin efflux  0 





























































chaJ XM_001258081   dipeptidase  4 X 10
 -100 
chaK XM_001258086   g-glutamylcyclotransferase  3 X 10
 -52 
chaP XP_750855 nonribosomal peptide synthase  0 
chaC AY838877 cytochrome P450   9 X 10
 -99 
chaI AY838877 PLP-dependent carbon–sulfur bond lyase 5 X 10
 -77 
chaN XM_002846230 methyltransferase 5 X 10
 -48 
Table 1-1. Putative (+)-chaetocin biosynthetic gene cluster from Chaetomium virescens (ATCC 26417).39 
 
Comparison of this putative cluster with known gliotoxin cluster revealed an 
additional cytochrome P450, ChaE, which the authors attributed to the dimerization of 
DKP monomers into the (+)-chaetocin dimeric scaffold however were unable to 
heterologously express and characterize this enzyme, and no genetic system for 
Chaetomium fungi had been described at that point. 
In 2014, Watanabe et. al. were also able to uncover the biosynthetic gene cluster 
for C2-symmetrical dimer (–)-ditryptophenaline (25) from Aspergillus flavus through 
disruption of the NRPS, DtpA.41 This gene cluster consisted of an NRPS (DtpA), N-
methyltransferase (DtpB), and cytochrome P450 (DtpC). Watanabe et. al. established 
the role each of these genes through disruption in vivo, as well as reconstitution of the 
native enzymatic activity of DtpC in vitro through incubation of biosynthetic DKP 
precursor 78 with microsomal fractions of S. cerevisiae expressing DtpC to yield (–)-
ditryptophenaline, 25. Wild-type DtpC displayed modest biosynthetic flexibility, and 
when DtpC containing microsomal fractions were incubated with non-cognate 
diketopiperazines, known natural products 80 and 81 were obtained and the authors 
were able to use this approach to generate milligram quantities of these dimers (5.6mg 




Figure 1-17. (–)-Ditryptophenaline 25 gene cluster and compounds generated through microsomal reactions. 41 
 
Recently, the biosynthetic gene cluster for related C2-symmetric dimer (+)-
verticillin A (3) as also discovered from Clonostachys rogersoniana and disruption of 
putative NRPS, verA, abolished production of (+)-verticillin (3) in vivo.42 In a survey of 
biosynthetic gene clusters from Aspergillus tubingensis G131, a known producer of (+)-
asperazine (53), a putative gene cluster for non-symmetrical was also disclosed.43 
 
1.10 Specific Aims 
The structural diversity and biological activity of dimeric DKPs are very diverse 
and dependent on stereochemistry and site of dimerization. In spite of the 
pharmaceutical potential of these compounds, the majority of in-depth biological study is 
are from dimeric DKPS containing the epidisulfide bridge from the 
epipolythiodiketopiperazine (ETP) family, likely do to the high titers from fermentation 
and commercial availability of members of this class. However, as noted in isolations of 
the non-thiolated dimers, the lack of their availability of these materials inhibits a full 
examination of their pharmaceutical potential.13 Development of methods for total 
synthesis of these molecules has forwarded the ability assess this potential, as well as 
structure activity relationships, and although there are >20 total syntheses for dimeric 
diketopiperazines, all of these syntheses are substrate controlled, and to date there 
exists no method which allows for selective construction of two isomers of different 





















































































The ultimate goal of this biosynthetic study is to uncover the biosynthetic 
machinery involved in the bacterial biosynthesis of diketopiperazine dimers, and to 
utilize these enzymes as biocatalysts for the synthesis and biological evaluation of 
known diketopiperazine dimer and novel derivatives. The focus of this dissertation is the 
site- and stereoselectivity of enzymes involved in the selective dimerization of 
diketopiperazines. Bioinformatic analysis of multiple Streptomyces revealed that in the 
biogenesis of unsymmetrical diketopiperazines dimers are derived from a 
diketopiperazine generated by a cyclodipeptide synthase (CDPS) which are oxidatively 
dimerized by a cytochrome P450 (P450). Thus, through heterologous gene expression 
and in vitro enzymatic assays, we propose to: a) identify key enzymes involved in site - 
and stereoselective assembly of non-symmetrical diketopiperazine dimers and; b) to 
probe the catalytic mechanism and selectivity of these enzymes through X-ray 
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Discovery and Characterization of NascB and NznB, Site- and 
Stereodivergent Diketopiperazine Dimerizing Cytochromes P450  
 
2.1. Abstract 
In this chapter, we describe the identification of two biosynthetic gene clusters 
from Streptomyces sp. CMB-MQ030 encoding the biosynthesis of the (+)-naseseazines, 
nzn gene cluster) as well as regio- and stereoisomeric cyptic natural products, the (–)-
naseseazines (nasc gene cluster).  Both gene clusters are composed of a 
cyclodipeptide synthase (CDPS) and cytochrome P450. The products of the 
cyclodipeptide synthases were characterized through in vivo expression and isolation of 
DKPs from the media. The P450s from these clusters were expressed and 
characterized in vitro as the first cytochrome P450s characterized which catalyze site- 
and stereodivergent C–H functionalization in a carbon-carbon and carbon-nitrogen bond 
forming cascade. This work was enabled through great help from Dr. Yogan Khatri who 
assisted in optimizing expression of the cytochromes described in this chapter, as well 
as Dr. Fengan Yu who initially annotated the gene clusters. 
 
2.2. Introduction 
Dimeric diketopiperazines are structurally complex natural products whose 
biological activities are intimately linked to the connectivity of the two diketopiperazine 
(DKP) monomers.1-3 While the isolation of DKP dimers from filamentous fungi dates 
back nearly fifty years,4 their corresponding biosynthetic gene clusters have only been 
recently identified through genome sequencing, gene disruption, and heterologous 
expression.5-7 Preliminary characterization of these fungal pathways indicates that 
biosynthetic cytochromes P450 mediate the oxidative convergence of two DKP 
monomers to generate C2 symmetrical dimers, validating long-standing hypotheses 
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proposed in isolation, characterization, and total syntheses of these molecules.7 
However, direct biochemical studies of cytochromes P450s that catalyze formation of 
microbial-derived DKP dimers has been stymied due to the lack of suitable protein 
expression systems for their direct study in vitro. 
Biological activity and exigent structural features native to C2 symmetrical dimeric 
DKPs, such as the sterically encumbered vicinal chiral quaternary carbons about the C2 
symmetry axis, elicited development of elegant synthetic methodologies towards the 
total synthesis of these compounds. Among them, biomimetic strategies have enabled 
efficient access to these natural products as two monomers may be identically 
functionalized and coupled at a late stage resulting in highly convergent syntheses. The 
selective chemical synthesis of the exotic non-symmetrical DKP dimers pose a 
comparable synthetic challenge as they require independent synthesis of two dissimilar 
subunits, each with appropriate functionalization to guide site- and stereospecific 
formation of the desired C–C or C–N bond upon dimerization. 8-10   
These non-symmetrical dimers were previously exclusively  isolated from fungi,11-
13 however marine Actinobacteria have recently emerged as a new source for these rare 
non-symmetrical dimers, and notably all DKP dimers isolated from bacterial sources to 
date have lacked symmetry elements (Figure 2-1).14-16  
 
Figure 2-1. Representative examples of fungal diketopiperazine dimers and bacterial diketopiperazine dimers 





































































































Representative Fungal Diketopiperazine Dimers
Bacterial Diketopiperazine Dimers Isolated to Date
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Furthermore, there are multiple reports of co-isolation of constitutional isomers of 
a given DKP dimer from the same organism, giving rise to two possible biosynthetic 
hypotheses: 1) a single oxidase has flexibility in dimerization and generates multiple 
products as a result of active site plasticity, or 2) each constitutional outcome is the 
result of a discrete oxidase with a high degree of selectivity. Identification of the 
bacterial biosynthetic enzymes responsible for non-symmetrical DKP dimer biogenesis 
may provide ready access to synthetically useful biocatalysts for selective assembly of 
this challenging class of natural products, and offers new opportunities to study late-
stage enzymatic C–H functionalization and C–C bond formation. 
 
2.3 Research and Discussion 
Streptomyces sp. CMB-MQ030 was the first bacterial strain from which the 
unsymmetrical DKP dimers (+)-naseseazines A (1) and B (2) were isolated.14 This strain 
was obtained, sequenced and mined for non-ribosomal peptide synthetase (NRPS) 
containing gene clusters based on known fungal biosynthetic systems.7 This effort failed 
to reveal any relevant NRPS-driven systems containing cytochrome P450s, however we 
identified three cyclodipeptide synthase (CDPS) driven candidate biosynthetic gene 
clusters (BGCs), each containing a cytochrome P450 from which the (+)-naseseazines 
A (2) and B (1) may be derived from (Figure 2-2). Based on these biosynthetic gene 
clusters, as well as structural analysis of 1 and 2, we proposed the diketopiperazine 
monomers are biosynthesized by a CDPS followed by dimerization by a downstream 
cytochrome (Figure 2-3). 
 































































Figure 2-3. Cyclodipeptide synthase (CDPS) containing gene clusters. 
 
Annotation of the surrounding genes in each CDPS gene cluster revealed that 











orf1 orf2 orf3 orf4 orf5 orf6 orf7 orf8
Dehydrogenase [S. marina]
Short-chain dehydrogenase [S. griseoaurantiacus]
XRE family transcriptional regulator [N. brasiliensis]
AlbC [Nocardiopsis sp. CNS639]
Cytochrome P450 [A. mirum]
Multi-drug efflux MFS permease [R. ruber]
F420-dependent oxidoreductase [A. marinum]






















orf1 orf2 orf3 orf4 orf5 orf6 orf7 orf8
Serine/threonine protein kinase [S. acidiscabies]
Hypothetical protein
Alpha amylase [S. cryophillis]
AlbC [Nocardiopsis sp. CNS639]
Cytochrome P450  CYP121 [S. rimosus]
LuxR transcription regulator  [S. flavogriseus]
Histidine kinase [S. griseoaurantiacus]






















orf1 orf2 orf3 orf4 orf5 orf6orf7 orf8
D-Ala-D-Ala carboxypeptidase [A. vancoresmycina]
LuxR regulator [S. rimosus]
Histidine kinase [Streptomyces sp. TOR3209]
AlbC [Nocardiopsis sp. CNS639]
Cytochrome P450  CYP121 [S. rimosus]
N-methyl-transferase [S. alboniger]
Nitroreductase [Nocardiopsis halotolerans]
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CDPS, and as the (+)-naseseazines contain no exocyclic unsaturation,17 we 
hypothesized that this gene cluster is likely not responsible for the biosynthesis of the 
naseseazines, leaving two gene clusters, nasc and nzn, both containing a CDPS and 
P450 within the same operon. Alignment of these two clusters showed high sequence 
homology for both the CDPS (Figure 2-4) and P450s (Figure 2-5) and an overall lack of 
homology to characterized homologues in the NCBI. In order to determine whether 
these gene clusters were responsible for the biosynthesis of the (+)-naseseazines the 
two CDPS, NascA and NznA, and respective P450s, NascB and NznB, were selecting 
for heterologous expression and characterization. 
 
 
Figure 2-4. Sequence alignment for NascA and NznA CDPSs. Identical residues are highlighted in red, yellow are 
similar, and consensus sequence below. 
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Figure 2-5. Sequence alignment of NascB and NznB P450s. 
 
2.3.1 Identification of CDPS Products Through In Vivo Analysis 
When heterologously expressed in E. coli, CDPSs utilize endogenous aminoacyl-
tRNAs as substrates to generate DKPs which are secreted into the media via an 
unknown mechanism. Upon expression of NascA, 8 was identified as the sole 
metabolite of the fermentation culture. Based on our biosynthetic hypothesis, 8 is a 
precursor to both 1 and 2, and as such we hypothesized that the nasc BCG may be 
responsible for the biosynthesis of the (+)-naseseazines. Expression of NznA, 8 and 9 
were identified as secreted metabolites, presenting all the required precursors required 
for construction of 1 and 2. However, while we found the P450 from the nasc gene 
cluster to be readily obtained through heterologous expression in E. coli, the 
cytochrome from the nzn cluster, NznB, was intransigent to this approach regardless of 
promoter, cell line, codon optimization, or co-expression with chaperones and 






Figure 2-6. HPLC traces from extraction of CDPS expression media from NascA, NznA and Node 92 CDPS. 
 
2.3.2 Characterization of Cytochrome P450, NascB 
For purposes of scale, 9 was synthesized as previously described,3, 8 and the 
binding of 9 to NascB was assessed via spectrophotometry. The interaction showed a 
clear low-spin to high-spin transition, characteristic of direct binding of the substrate to 
the enzyme active site affirming that this cytochrome P450 may .18  
Incubation of 9 with NascB, ferredoxin and ferredoxin reductase from Spinacia 
oleracea19-20, and NADPH led to formation of a single product whose mass 
corresponded to the predicted DKP dimer, (+)-naseseazine B (1), as assessed by LC-
MS (Figure 2-7). To determine the structure of this dimeric product, a 10mg scale 
NascB-catalyzed dimerization was performed and crude products purified by 






Figure 2-7. HPLC trace from NascB reaction with 9. 
  
Detailed evaluation of the 1H NMR spectrum of the NasB catalyzed dimerization 
product of DKP 9 revealed significant differences with spectroscopic data for (+)-
naseseazine B (1).  These differences were also evident in the 13C NMR and 
subsequent 2D NMR spectra. With mass spectrometry supporting the formation of a 
dimeric compound, we compared the NMR data against spectra from known dimers of 9 
dimers.7, 15-16, 21 The 1H NMR data from the product of the NascB reaction aligned 
favorably with that reported for “new iso-naseseazine B”,15,22 the C3(R)-diastereomer of 
(+)-naseseazine B (11). However, the structure of “new iso-naseseazine B”22 had been 
disputed in a later isolation report, which reassigned the dimerization axis from C3–C6' 
to the unprecedented C3–C5' linkage23 and renamed the molecule naseseazine C (4) 
(Figure 2-8).16 However, the use of different solvents in the reports describing the 
structure of the “new iso-naseseazine B (11)”22 and naseseazine C (4) prevented their 



































Figure 2-8. Structures of (+)-naseseazine B (1), synthetic (+)-iso-naseseazine B (10) proposed structure of  “new iso-
naseseazine B (11), and naseseazine C (4) 
 
2.3.3 Total Synthesis of (–)-naseseazine C (4) and (–)-iso-naseseazine C (10) 
To validate the structure of the NasB dimerization product, we opted to access 
both potential regioisomers recently reported as new naseseazines15-16 through 
chemical total synthesis in collaboration with the Movassaghi lab (MIT).  This enabled 
full structural assignment of these alkaloids in both methanol-d4 and DMSO-d6, and 
direct comparison with the new product 4 isolated from the NascB mediated 
dimerization of DKP 9.  
Exposure of (–)-12 to silver hexafluoroantimonate in the presence of 13 led to a 
1:1.4 (C5’:C6’) regioisomeric mixture of dimers (–)-14 and (–)-15 in 40% combined yield 
(Scheme 1). 24 Notably, the same ratio of regioisomers has been observed in the first 
generation synthesis of dimeric DKP alkaloids, (+)-naseseazine A (2) and (+)-
naseseazine B (1).8 Hydrogenolytic removal of the carboxybenzyl groups afforded both 
C5' and C6' constitutional isomers in 80% and 84% yield, respectively. All spectroscopic 
data for the C5' isomer 4 were consistent with the literature data for both (–)-


































“new” iso-naseseazine B (11)
Streptomyces sp. SMA-1

















































Figure 2-9. Total synthesis of (–)-naseseazine C (4) and (–)-isonaseseazine C (16) 
 (a), AgSbF6, EtNO2, (–)-14:(–)-15 = 1:1.4, 40%. (b) H2/Pd/C, EtOH, (80% for (–)-4 and 84% for (–)-16. 
 
Furthermore, the spectroscopic data for the C6' isomer termed iso-naseseazine 
C (16)25 was not consistent with data reported for either (–)-naseseazine C or “new iso-
naseseazine B”. Based on these results, we confirm the relative and absolute 
stereochemistry of (–)-naseseazine C (7) as the C3(R)-DKP dimer with C3–C6' linkage. 
Additionally, we were able to revise the optical rotation for (–)-naseseazine C (observed: 
[α]D23 = –180 (c = 0.16, MeOH); lit.: [α]D23 = –18.6 (c = 0.004 MeOH)16). Notably the 
magnitude of the observed optical rotation for our synthetic sample of (–)-naseseazine 
C (7) is consistent with other members of this family of alkaloids.9-10, 26 Importantly, with 
both regioisomers in hand and with confirmation of the structure of  (–)-naseseazine C, 
we were able to validate its assignment as the direct product of the dimerization event 
of brevianamide F catalyzed by NasB. 
Although (–)-naseseazine C (4) was not detected under the reported 
fermentation conditions from which (+)-naseseazines A (1) and B (2) were obtained, the 
isolation of isomeric diketopiperazine dimers from a single organism is not uncommon 
(Figure 2-10).12-13 Based on this literature precedent, and the products of the CDPS, 
NznA, we hypothesized that the (+)-naseseazines may be produced by the nzn 



















(–)-iso-naseseazine C, R=H (20)
(–)-14, R=Cbz








































Figure 2-10. Examples of isomeric DKP dimers isolated from a single organism. 
 
2.3.4 Expression and Characterization of Cytochrome P450, NznB 
Alternative start sites for biosynthetic genes are well known in Streptomyces27 
and the start site for this NznB was annotated through a sequence alignment using 
NascB as a template. Upon further analysis, we identified two in-frame putative 
alternative start sites at -30nt and -60nt of the originally annotated NznB start site. 
Extension of a codon-optimized gene to generate constructs with start sites at -30nt and 
-60nt and co-expression of chaperones via co-transformation with pGro7 plasmid 
enabled soluble expression of this NznB, with the -30 site garnering a dramatically 


























































































Figure 2-11. Top: Sequence alignments of NascB and NznB P450s and alternative start sites highlighted in red. 
Bottom: SDS-Page gel from expression of NznB+09 (-30nt, left)  and NznB+19 (-60nt, right). Lanes for both 
expressions from left to right: 1) Ladder, 2) Pellet, 3) supernatant, 4) 25mM imidazole wash, 5) 50mM imidazole 
Wash, 6) 200mM imidazole elution. 
 
Binding of CDPS products 8 and 9 to NznB was assessed via spectrophotometry 
and both induced a clear low-spin to high-spin transition. Incubation of 9 with NznB, 
ferredoxin (Fdx) and ferredoxin reductase (FdR) from Spinacia oleracea19-20, and 
NADPH led to formation of a single product whose mass corresponded to homodimeric 
(+)-naseseazine B (1) as assessed by LC-MS, and upon scale up and isolation was 
confirmed by NMR to be (+)-naseseazine B (Figure 2-11).8 (+)-naseseazine A is a 
heterodimer composed as 8 and 9, and when combined together in equimolar quantities 
with NznB, Fdx, and FdR the major product of the reaction has a mass corresponding to 
(+)-naseseazine A (2). While the homodimer of 9, (+)-naseseazine B (1), and the 
heterodimer of 8 and 9, (+)-naseseazine A (2), are both reported in the original isolation 
report, the homodimer of 8 was absent. However a peak who’s mass corresponded to 
this product was observed in minute quantities from the heterodimerization reaction of 8 
and 9 with NznB. Upon incubation of only 8 with NznB, Fdx, and FdR, a single product 
was once again formed in high yield and high conversion whose mass corresponded to 





























































































2.3.5 In vitro Simulation of Putative Biosynthetic Cross-Talk 
Tailoring of DKP natural products from oxidative enzymes via “biosynthetic 
crosstalk” has been observed in the biosynthesis of both bacterial, and fungal 
secondary metabolites, such as the erythrochelin28 and spirotryprostatins,29 
respectively. Given the high sequence homology between both the nasc and nzn BGCs, 
we hypothesized that DKP 8 generated by NznA, and not NascA, may be accepted as a 
dimerization substrate by NascB via such pathway crosstalk. To simulate the possibility 
for this crosstalk in vitro, co-incubation of 8 and 9 resulted in a product who’s mass 
corresponds to a single heterodimer (Figure 2-13). Curiously, incubation of 8 alone with 
NascB results in an ~1:1 mixture of two products whose masses correspond to 
formation of a homodimer. We hypothesize the homodimerization of 8 resulting in two 
constitutional isomers is due to the loss of steric bulk on the substrate (alanine relative 
to proline), and therefore decreased molecular recognition by NascB leading to loss of 
selectivity and the formation of multiple products. The formation of a single DKP 
heterodimer corroborates this hypothesis, as the larger proline side chain “rescues” the 






Figure 2-13. HPLC traces from reactions of 8 and 9 with NascB.  
 
2.4 Conclusion 
We identified the biosynthetic gene clusters for the biosynthesis of the (+)-
naseseazines as well as the cryptic (–)-naseseazines and validated our biosynthetic 
hypothesis wherein cyclodipeptide synthases NascA and NznA generated 
diketopiperazine precursors 8 and 9 which were then dimerized to (+)-naseseazine or (–
)-naseseazine scaffolds by NznB and NascB respectively. In vitro characterization of the 
cytochromes demonstrated that NascB and NznB are site- and stereodivergent 
biocatalysts, with NascB forming the C3-C5’ linked diketopiperazine dimers with exo-
stereochemistry such as (–)-naseseazine C (4), and NznB forming C3-C6’ linked dimers 
with endo chemistry such as (–)-naseseazine B (1). Identification and initial 
characterization of these gene clusters may enable the use of these biocatalysts in the 
























Figure 2-14. Comparison of (–)-naseseazine C (4) and (+)-naseseazine B (1) structures. 
 
We also generated previously unreported dimer 20 (structure under assignment) 
and simulated biosynthetic crosstalk between these two clusters demonstrating DKP 8, 
produced only in the nzn cluster by NznA, can act as a substrate in dimerization 
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All UV-Visible spectra were acquired using a single beam Molecular Devices Spectra 
Max M5 spectrophotometer, with a 1 cm quartz cuvette. Analytical HPLC data was 
acquired using a Shimadzu HPLC system comprised of two LC-20ADXR pumps, a SIL-
20ACXR autosampler, and a SPD-M20A diode array detector. Preparatory HPLC was 
performed using a Beckman Coulter stack comprised of a System Gold 125 solvent 
module, 168 detector, and SC100 fraction collector. Isothermal titration calorimetry 
experiments were conducted in a Nano-ITC Low volume (TA Instruments). 1H NMR 
spectra were recorded on Varian 600 MHz spectrometers and are reported relative to 
residual solvent peak (CD2HOD: δ 3.31). 13C NMR spectra were reported relative to 
residual solvent peaks (CD2HOD: δ 49.0). 
 
Streptomyces sp. CMBMQ-030 genomic DNA sequencing 
The genomic DNA of Streptomyces sp. CMB-MQ030 was extracted and purified as 
prescribed using the Promega Wizard® Genomic DNA Purification Kit. The genomic 
DNA (2x250 bp paired-end) was sequenced using Illumina HiSeq 2500 sequencing 
system at University of Michigan DNA Sequencing Core. Briefly, the genomic DNA 
sample was first sheared to approximately 500 nucleotide average fragment size, then 
Illumina-compatible sequencing libraries were prepared from those fragments on an 
Apollo 324 robotic workstation (WaferGen Biosystems), using the Kapa HTP Library 
Preparation Kit (KAPABiosystem) according to the manufacturer’s protocols. 
Subsequent libraries were sequenced on an Illumina HiSeq 2000, obtaining paired-end 
sequence data with 100 nucleotide reads at each end, as per recommended protocols 
from Illumina, Inc. The generated next-generation sequencing data were then de 
novo assembled using Velvet 1.2.10.1  
 
																																																								
1 Zerbino, D. R.; Birney, E., Gen. Res. 2008, 18 (5), 821-829. 
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Supplementary Table 2-1. Summary of genome assembly dataset and parameters 
Genome Number of reads k-mer Coverage 
cutoff 




33,263,004 51 10 66,868 591 
 
Cloning of NascA, NascB, and NznA 
The PCR primers were designed to introduce an NdeI restriction site at the 5′ end of the 
fragment and a HindIII restriction site 3′ end, respectively. The coding sequences were 
amplified from the genomic DNA of Streptomyces sp. CMB-MQ030 using primers for 
the associated target gene (NasA, primer 1 &2, NasB primer 3 & 4). The expression 
constructs were designed in pET21b vector via NdeI and HindIII restriction sites. The 
nucleotide sequences were confirmed by automated sequencing (University of Michigan 
DNA Sequencing Core). 
 
Supplementary Table 2-2. Primers used in cloning NascA, NasB, NznA, NznB, and 
extending codon optimized sequence of NznB 
Primer # Gene Primer Rest. Site 5’→3’ 
1 NascA Forward NdeI CCAACCcatatgGTGAACACTTCCCTCGCTGCGG
TGGCCGGC 
2 NascA Reverse HindIII CCAACCaagcttGCGTTCGGCCGCCCGGTCCCG
CAGCAGGAT 
3 NascB Forward NdeI CCAACCcatatgGTGACCACCACCGCCACGCTGA
CCTACCCC 
4 NascB Reverse HindIII CCAACCaagcttCCAGGTGGCGGGAAGCGCCCG
CGGACGGCG 
5 NznA Forward NdeI CCAACCcatatgATGGCCACACACGCCTCCGCAC
CCGCACCC 
6 NznA Reverse HindIII CCAACCaagcttCTGCTGCGTCACGCGGTCCTTG
AGGAG 
7 NznB Forward NdeI CCAACCcatatg 
GTGACCACCGCACCGGTCCCCCTCACCTTC 
8 NznB Reverse HindIII CCAACCaagcttCCAGGAAGCGGGGATCGCCTT




9 NznB (CO) +09 Forward  GTGGATCCGTATACCAAAGAATGCCGTACCGT
GACCACCGCGCCGGTTCCGCT 
10 NznB (CO) +19 Forward  GTGATTCGTCCGCAGCCGCATCGTAGCCCGGT
GGATCCGTATACCAAAGAATGCCGTACCGTGA
CCACCGCGCCGGTTCCGCT 
Note: Lowercase sequences represent restriction sites. 
 




























Overexpression and analysis of NasA and NznA. 
The expression of pET21b-NasA was performed by transforming the plasmid into 
the competent cell E. coli strain C41(DE3) and selected on Luria-Bertani (LB) medium 
plates containing 100 µg/mL ampicillin. A single colony was grown overnight in 5 mL LB 
broth containing the same concentration of the antibiotics. The main culture was 
prepared by inoculating 1% with overnight culture into a 2 L baffled flask containing 1 L 
of LB containing 100 µg/mL ampicillin. The cultures were incubated at 37°C and 250 
rpm for 3-4 h until absorbance A590nm = 0.6. The expression of NasA was induced by the 
addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The cultures were 
incubated further at 18°C for 18 h shaking at 180 rpm. Cells were harvested by 
centrifugation at 5000×g at 4°C for 15 min and a 1 mL aliquot of the supernatant was 
extracted with 1 mL CHCl3 (3x). The organic extracts were dried and solvents were 
removed en vacuo. Residue was resuspended in 100 uL of HPLC grade methanol for 
HPLC analysis in which the samples was resolved using a linear gradient of 5-100% 
acetonitrile: water (0.1% formic acid) over 30 min (1.5 mL/min flow rate) on a 
Phenomenex Luna 5µ C-18(2) 100A, 250 × 4.60mm 5 micron column. 
 
 
Overexpression, purification and spectral characterization of cytochrome P450 
NascB 
The expression of pET21b-NasB was performed by transforming the plasmid into 
the competent cell E. coli strain C41(DE3) and selected on Luria-Bertani (LB) medium 
plates containing100 µg/mL ampicillin. A single colony was grown overnight in LB broth 
containing the same concentration of the antibiotics. The main culture was prepared by 
inoculating 1% of each overnight culture into a 2 L baffled flask containing 500 ml of 
Terrific Broth (TB) containing 100 µg/mL ampicillin. The cultures were incubated at 37°C 
and 250 rpm for 3-4 h unless the absorbance A590nm = 1. 0.5 mM delta-5-aminolevulinic 
acid (w/v) was added and expression of NascB was induced by the addition of 0.8 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG). The cultures were incubated further for 
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36 h, 28°C at 160 rpm. Cells were harvested by centrifugation at 5000×g at 4°C for 10 
min and the cell pellet was stored at –80°C until purification of the protein. 
 
The cell pellet was resuspended in 5% culture volume of lysis buffer (50 mM Tris, 
pH 7.4 containing 50 mM NaCl, 2% glycerol, 0.5 mM EDTA, 10 mM beta-
mercaptoethanol and 1mM phenylmethane sulfonyl fluoride (PMSF) and disrupted by 
sonication. The cell lysate was centrifugated (35,000 rpm for 35 min) and filtered (0.2 
µM Millipore filter). The soluble His6-tagged NasB was purified by affinity 
chromatography using Ni-NTA (Qiagen) column and the collected fractions were 
analyzed by SDS-PAGE. The suitable red fractions were pooled and dialyzed at 4°C 
three times using 50 mM Tris, pH 7.4 containing 10% glycerol, 50 mM NaCl and 1 mM 
dithiothreitol (DTT) against a total of 6 L buffer. 
 
Overexpression, purification and spectral characterization of cytochrome P450 
NznB 
The expression of pET28b-NznB+09 was performed by transforming the plasmid 
into the competent cell E. coli strain C41 (DE3) and selected on Luria-Bertani (LB) 
medium plates containing100 µg/mL kanamycin. A single colony was grown overnight in 
LB broth containing the same concentration of the antibiotics. The main culture was 
prepared by inoculating with 1% overnight culture into a 2 L baffled flask containing 500 
ml of Terrific Broth (TB) containing 100 µg/mL kanamycin. The cultures were incubated 
at 37°C and 250 rpm for 3-4 h unless the absorbance A590nm = 1. 0.5 mM delta-5-
aminolevulinic acid (w/v) as well as 1mM thiamine were then added and the expression 
of NznB was induced by the addition of 0.8 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG). The cultures were incubated further for 30 h, 18°C at 160 rpm. Cells were 
harvested by centrifugation at 5000×g at 4°C for 10 min and the cell pellet was stored at 
–80°C until purification of the protein. 
 
The cell pellet was resuspended in 5% culture volume of lysis buffer (50 mM kPi, 
pH 8.0 containing 200 mM (NH4)2SO4, 20% glycerol, 0.5 mM EDTA, 10 mM beta-
mercaptoethanol and 1mM phenylmethane sulfonyl fluoride (PMSF) and disrupted by 
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sonication. The cell lysate was centrifugated (35,000 rpm for 35 min) and filtered (0.2 
µM Millipore filter). The soluble His8-tagged NznB was purified by affinity 
chromatography using Ni-NTA (Qiagen) column and the collected fractions were 
analyzed by SDS-PAGE. The suitable red fractions were pooled and dialyzed at 4°C 
three times using 50 mM Tris, pH 7.4 containing 50 mM kPi, pH 8.0 containing 200 mM 
(NH4)2SO4, 20% glycerol, 0.5 mM EDTA, and 1 mM dithiothreitol (DTT) against a total of 
6 L buffer. 
 
UV–Vis spectra for the purified cytochomes were recorded at room temperature in 
buffer (50 mM Tris-HCl buffer, pH 7.4 containing 5% glycerol) was used for the spectral 
measurements of the oxidized and reduced form. NasB was reduced by the addition of 
a small amount of sodium dithionite. The concentration of the P450s was estimated by 
CO-difference spectra, assuming ε(459–490) = 91 mM−1 cm−1 according to the method 
of Omura and Sato.  
 
General reaction conditions for analytical scale P450 reactions 
The conversion of DKPs by P450s were carried out with the heterologous redox 
electron partners Fdx and FdR from S. olerecea. A protein ratio of P450: Fdx: FdR of 1: 
20: 3 was used. The in vitro reaction mixture included 50 mM Tris-HCl, pH 7.4, 0.5 µM 
P450, 10 µM Fdx and 1.5 µM FdR at the end volume of 250 µL. Without exceeding 1% 
of the total reaction volume, 200 µM of DKP dissolved in DMSO was added. The 
reaction was initiated by adding NADPH (1 mM). Two of the control reactions including 
all the contents except for NADPH or P450 were used as controls. The reactions were 
incubated at 30°C for 1 h agitating at 600 rpm in a thermoshaker (Multi-thermoshaker, 
Benchmark). The conversion was stopped by adding an equal volume of chloroform and 
was extracted with chloroform for 3 times. The samples were dried under a stream of 
nitrogen and the residue was resuspended in 100 µL of HPLC grade methanol and 
analyzed by HPLC in which the reaction mixture was resolved using a linear gradient of 
5-100% acetonitrile: water (0.1% formic acid) over 30 min (1.5 mL/min flow rate) on a 
Phenomenex Luna 5µ C-18(2) 100A, 250 × 4.60mm 5 micron column. 
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General reaction conditions for preparatory scale P450 reactions 
Large scale reaction were performed in 84 identical reactions as described above. The 
reactions were combined after 2 hours, diluted with 1 volume of brine and quenched 
with 100 mL of CHCl3. The mixture was centrifuged at 5,000 X g and poured into a 
separatory funnel. The organic layer was partitioned and the aqueous layer was 
extracted 2 more times (100 mL each). The organic layers were combined, dried and 
solvent was removed en vacuo.  
 
Prep-Scale Synthesis of (–)-naseseazine C (4) 
Procedure above was followed with DKP 9, as a substrate and NascB as P450. 
Residue was diluted in 8 mL HPLC grade methanol, sonicated to solvate, and filtered 
through a 0.2 µm syringe filter. The filtered solution was then purified via preparative 
HPLC (Luna preparative HPLC column, C18, 5 µm, 21.2 × 250 mm;) using gradient of 
5% to 100% acetonitrile in water containing 0.1% formic acid at the flow of 7.0 mL/min 
for 60 min. The retention time (tR) of 7 was  31.2 min. The product fractions were 
pooled, solvent was removed en vacuo, to give 8 mg of (–)-naseseazine C which was 
used for detailed NMR characterization without any further purification. 
 
Prep-Scale Synthesis of (+)-naseseazine B (1) 
Procedure above was followed with DKP 9, as a substrate and NznB as P450. Residue 
was diluted in 8 mL HPLC grade methanol, sonicated to solvate, and filtered through a 
0.2 µm syringe filter. The filtered solution was then purified via preparative HPLC (Luna 
preparative HPLC column, C18, 5 µm, 21.2 × 250 mm;) using gradient of 5% to 100% 
acetonitrile in water containing 0.1% formic acid at the flow of 7.0 mL/min for 60 min. 
The retention time (tR) of 7 was  34.1 min. The product fractions were pooled, solvent 
was removed en vacuo, to give 11 mg of (+)-naseseazine B which was used for detailed 
NMR characterization without any further purification. 
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Supplementary Figure 2-1. Sample Prep-HPLC trace from purification of 4 from 
large scale conversion of 9 by NascB.  
 
 
Steady state kinetics of conversion of brevianamide F (9) to (–)-naseseazine C (4) 
by NasB 
In order to capture the steady state, the concentration of NascB and 9 had to be 
significantly lower than in previous enzymatic reactions. As such to visualize product 
formation, reaction volume was scaled up to 2 mL containg NascB (30 nM), Fdx (600 
nM), and FdR (90 nM), and the substrate concentrations were varied from 2.5-100 µM. 
Reactions were initiated with the addition of NADPH (1mM final concentration), and 
quenched at 2 min intervals with the addition of 1 mL of CHCl3 and vortexing at high 
speeds for 30s. An additional 500 uL of CHCl3 was added and 800 uL of organic layer 
was removed, and this was repeated 2 more times. Solvents were removed en vacuo, 
and residue was resuspended in 100 uL of HPLC grade methanol, and analyzed by 
HPLC in which the reaction mixture was resolved using a linear gradient of 20-55% 
acetonitrile : water (0.1% formic acid)  for 12 min (1.5 mL/min flow rate) on a 
Phenomenex Luna 5 µ C-18(2) 100A, 250 × 4.60 mm 5 micron column. Initial velocities 
were determined based on the formation of 7 and quantified using a standard curve. 
Initial velocities were plotted against substrate concentration and fit by non-linear 
regression to the Michaelis-Menten equation using GraphPad Prism Version 6.01 to 
determine the kinetic constants kcat and KM. 
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Supplementary Figure 2-2. Steady state kinetics of 9 conversion by NascB.  
The Michaelis-Menten hyperbolic fit for [naseseazine C (9, nM)] /min vs [brevianamide F 
(4, nM) ] is shown. The inset showed the capture of steady state product formation (nM) 
using varying concentration (2.5 µM–100 µM) of 9 at varying time interval (2 min to 10 




Supplementary Table 2-3. Steady state kinetics of 6 conversion by NasB.  
Enzyme Substrate Kcat (s-1) KM (µM) kcat/KM (M-1 s-1) 




General Procedures. All reactions were performed in oven-dried or flame-dried round-
bottom flasks. The flasks were fitted with rubber septa and reactions were conducted 
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under a positive pressure of argon. Gas-tight syringes with stainless steel needles or 
cannulae were used to transfer air- and moisture-sensitive liquids. Where necessary (so 
noted), reactions were performed in Schlenk tubes fitted with a PTFE stopcock. Flash 
column chromatography was performed as described by Still et al. using granular silica 
gel (60 Å pore size, 40–63 µm, 4–6% H2O content, Zeochem).2 Analytical thin layer 
chromatography (TLC) was performed using glass plates pre-coated with 0.25 mm 230–
400 mesh silica gel impregnated with a fluorescent indicator (254 nm). TLC plates were 
visualized by exposure to short wave ultraviolet light (254 nm) and an aqueous solution 
of ceric ammonium molybdate (CAM) followed by heating on a hot plate (~250 ºC). 
Organic solutions were concentrated at 29–30 °C on rotary evaporators capable of 
achieving a minimum pressure of ~2 torr.  
 
Materials.  Commercial reagents and solvents were used as received with the following 
exceptions: dichloromethane, acetonitrile, tetrahydrofuran, methanol, pyridine, toluene, 
and triethylamine were purchased from J.T. Baker (CycletainerTM) and were purified by 
the method of Grubbs et al. under positive argon pressure.3  Nitroethane was distilled 
over calcium hydride and stored over 4 Å molecular sieves. Silver hexafluoroantimonate 
was purchased from Strem Chemicals, Inc. All other solvents and chemicals were 
purchased from Sigma–Aldrich. 
 
Instrumentation.  Proton nuclear magnetic resonance (1H NMR) spectra were recorded 
with Varian inverse probe INOVA-500 and Varian INOVA-500 spectrometers, or a 
Bruker AVANCE III 400 spectrometer. Chemical shifts are reported in parts per million 
on the δ scale, and are referenced from the residual protium in the NMR solvent (CHCl3: 
δ 7.26, CD3SOCD2H: δ 2.50, CD2HOD: δ 3.31).4 Data are reported as follows: chemical 
shift [multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constant(s) 
in Hertz, integration, assignment].  Carbon-13 nuclear magnetic resonance (13C NMR) 
spectra were recorded with a Varian INOVA-500 spectrometer or a Bruker AVANCE III 																																																								
2 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.  
3 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518. 
4 G. R. Fulmer, A. J. M. Miller, N. H. Sherden, H. E. Gottlieb, A. Nudelman, B. M. Stoltz, J. E. Bercaw, K. I. Goldberg. 
Organometallics 2010, 29, 2176. 
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400 spectrometer and are reported in parts per million on the δ scale, and are 
referenced from the carbon resonances of the solvent (CDCl3: δ 77.16, DMSO-d6: δ 
39.52, CD3OD: δ 49.00). Data are reported as follows: chemical shift (assignment). Data 
are reported as follows: chemical shift (assignment).  Infrared data (IR) were obtained 
with a Perkin-Elmer 2000 FTIR, and are reported as follows: frequency of absorption 
(cm–1), intensity of absorption (s = strong, m = medium, w = weak, br = broad).  Optical 
rotations were measured on a Jasco-1010 polarimeter. UV-Vis spectrophotometric data 
were acquired on a Varian Cary 50 Bio UV-Vis spectrophotometer. Preprative HPLC 
was performed on a Waters system with the 1525 Binary HPLC Pump, 2489 UV/Vis 
Detector, 3100 Mass Detector, System Fluidics Organizer, and 2767 Sample Manager 
components. We thank Liam P. Kelly for obtaining the mass spectrometric data at the 
Department of Chemistry’s Instrumentation Facility, Massachusetts Institute of 
Technology.  High resolution mass spectra (HRMS) were recorded on a Bruker 
Daltonics APEXIV 4.7 Tesla FT-ICR-MS using either an electrospray (ESI) or direct 
analysis in real time (DART) ionization source. 
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Positional Numbering System. In assigning the 1H and 13C NMR data of all 
intermediates en route to our total syntheses of (–)-naseseazine C and (–)-iso-
naseseazine C, we wished to employ a uniform numbering scheme. This numbering 
system is also consistent with that employed in the isolation papers of (–)-naseseazine 







5 Buedenbender, L.; Grkovic, T.; Duffy, S.; Kurtbotke, D. I.; Avery, V. M.; Carroll, A. R. Tet. Lett, 2016, 57, 5893. 






























































(–)-iso-naseseazine C (8)(–)-naseseazine C (7)





Diketopiperazine bromide (–)-13: A sample of N-bromosuccinimide (641 mg, 3.60 
mmol, 3.00 equiv) was added in one portion to a stirred suspension of diketopiperazine 
14 (500 mg, 1.20 mmol, 1 equiv) in acetonitrile (60 mL). After 25 min, a solution of 
saturated aqueous sodium thiosulfate solution (30 mL) was added to the reaction 
mixture. After 10 min, the reaction mixture was diluted with ethyl acetate (30 mL), and 
washed with saturated aqueous sodium thiosulfate solution (30 mL). The aqueous layer 
was extracted with ethyl acetate (3 × 20 mL) and the combined organic layers were 
dried over anhydrous sodium sulfate, were filtered, and were concentrated under 
reduced pressure. The crude reaction mixture was purified by flash column 
chromatography on silica gel (eluent: 30→35% ethyl acetate in hexanes), including a 
second chromatographic purification (eluent: 30→35% ethyl acetate in hexanes) to 
afford exo-diketopiperazine bromide (–)-15 (90.5 mg, 14.8%) as an off-white foam along 
with an equal amount (~15%) of the corresponding endo-diastereomer (exo-DKP:endo-
DKP, 1:1). Structural assignments were made using additional information from gCOSY, 
HSQC, HMBC and nOe experiments. 1H NMR (MHz, CDCl3, 20 ºC): δ 7.69 (app-br-s, 
1H, C8H), 7.48 (app-d, J = 7.3 Hz, 2H, PhCbz-o-H), 7.43 (d, J = 7.7 Hz, 1H, C5H), 7.41–
7.30 (m, 4H, C7H, PhCbz-m-H, PhCbz-p-H), 7.16 (app-t, J = 7.5 Hz, 1H, C6H), 6.57 (s, 1H, 
C2H), 5.43 (d, J = 12.2 Hz, 1H, PhCbzCHa), 5.31 (d, J = 12.3 Hz, 1H, PhCbzCHb), 4.04 
(app-t, J = 8.2 Hz, 1H, C15H), 3.97 (dd, J = 5.9, 11.4 Hz, 1H, C11H), 3.62–3.45 (m, 2H, 
C19H), 3.35 (dd, J = 5.9, 13.2 Hz, 1H, C12Ha), 3.01 (dd, J = 11.0, 13.2 Hz, 1H, C12Hb), 
2.35–2.23 (m, 1H, C17Ha), 2.25–2.14 (m, 1H, C17Hb), 2.10–1.97 (m, 1H, C18Ha), 1.95–
1.80 (m, 1H, C18Hb). 13C NMR (100 MHz, CDCl3, 20 ºC): δ 165.8 (C16), 164.2 (C13), 
153.0 (NC=OCbz), 141.4 (C9), 135.8 (PhCbz-i-C), 132.0 (C4), 131.2 (PhCbz), 128.7 (C7), 
128.5 (PhCbz-o-C), 128.4 (PhCbz), 125.1 (C6), 123.9 (C5), 117.7 (C8), 83.3 (C2), 68.6, 
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film) cm–1:  2957 (w), 2887 (w), 1716 (s), 1674 (s), 1329 (m). HRMS (ESI) (m/z):calc’d 
for C24H23BrN3O4 [M+H]+: 496.0866, found: 496.0858.  [α]D24:  –168 (c = 0.46, CH2Cl2). 
TLC (70% ethyl acetate in hexanes), Rf: 0.22 (UV, CAM). 
 





meta-(−)-Nin,Nin'-Dicarboxybenzyl iso-Naseseazine C (14) and para-(−)-Nin,Nin'-
Dicarboxybenzyl Naseseazine C (15): Diketopiperazine bromide (–)-13 (100 mg, 
0.196 mmol, 1 equiv) and proline diketopiperazine 12 (245 mg, 0.588 mmol, 3.00 equiv) 
were azeotropically dried from anhydrous benzene (3 × 0.5 mL) and the residue was 
suspended in freshly distilled nitroethane (9.8 mL). Silver hexafluoroantimonate (202 
mg, 0.588 mmol, 3.00 equiv) was then added as a solid in a single portion. After 4.5 h, 
the reaction mixture was diluted with dichloromethane (15 mL) and washed with a 
mixture of saturated aqueous sodium bicarbonate and saturated aqueous sodium 
thiosulfate (10:1 v/v, 15 mL). The resulting aqueous layer was extracted with 
dichloromethane (3 × 10 mL) and the combined organic layers were dried over 
anhydrous sodium sulfate, were filtered, and were concentrated under reduced 
pressure. The crude reaction mixture was purified by flash column chromatography on 
silica gel (eluent: 10→50% acetone in dichloromethane) to afford a regioisomeric 
mixture of (–)-15 and (–)-14 (65.6 mg, 40.1%, (−)-17:(−)-16, 1.4:1) as a white foam. 
Regioisomers (−)-15 and (−)-14 were separated for the purpose of full and independent 
characterization by preparative HPLC [Luna preparative HPLC column, C18, 5 µm, 21.2 
× 250 mm; 7.0 mL/min; gradient, 5%→100% acetonitrile in water with 0.1% formic acid, 
60 min; tR((−)-15) = 48.3 min, tR((−)-14) = 50.4 min]. Structural assignments were made 
using additional information from gCOSY, HSQC, HMBC and nOe experiments.  
para-(−)-Nin,Nin'-Dicarboxybenzyl Naseseazine C (15): 1H NMR (500 MHz, CDCl3, 20 
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C5'H, PhCbz-H), 7.43–7.35 (m, 5H, PhCbz-H), 7.34–7.26 (m, 4H, C7H) PhCbz-H), 7.22 (d, J 
= 7.4 Hz, 1H, C5H), 7.10 (app-t, J = 7.5 Hz, 1H, C6H), 7.04 (d, J = 8.8 Hz, 1H, C7'H), 
6.61 (s, 1H, C2H), 5.69 (s, 1H, N10'H), 5.42 (app-s, 2H, PhCbz’CH2), 5.39 (d, J = 12.2 Hz, 
1H, PhCbz'CHa), 5.28 (d, J = 12.3 Hz, 1H, PhCbz’CHb), 4.31 (dd, J = 3.5, 10.7 Hz, 1H, 
C11'H), 4.15 (dd, J = 5.8, 11.3 Hz, 1H, C11H), 4.10 (app-q, J = 7.8 Hz, 2H, C15H, C15'H), 
3.69–3.47 (m, 5H, C12'Ha, C19H, C19'H), 3.16 (dd, J = 5.8, 12.9 Hz, 1H, C12Ha), 2.91–
2.82 (m, 2H, C12Hb, C12'Hb), 2.36–2.27 (m, 2H, C17'H), 2.27–2.11 (m, 1H, C17Ha), 2.11–
1.95 (m, 3H, C17Hb, C18H), 1.96–1.84 (m, 2H, C18'H). 13C NMR (125 MHz, CDCl3, 20 ºC): 
δ 169.5 (C16'), 166.0 (C16), 165.4 (C13), 164.9 (C13'), 153.1 (CCbz=O), 150.4 (CCbz'=O), 
141.5 (C9), 136.6 (C6'), 136.1 (PhCbz-i-C), 135.1 (C4), 134.8 (2C, C9', PhCbz'-i-C), 130.0 
(C4'), 129.3 (C7), 129.0 (2C, PhCbz-C), 128.8 (PhCbz-C), 128.6 (PhCbz-C), 128.3 (2C, 
PhCbz-C), 125.0 (C2'), 124.8 (C6), 124.0 (C5), 123.6 (C7'), 117.6 (C8), 116.3 (C8'), 116.0 
(C3'), 115.4 (C5'), 81.9 (C2), 69.2 (PhCbz'-CH2), 68.3 (PhCbz-CH2), 60.7 (C11 or C15'), 60.6 
(C11 or C15'), 59.3 (C15), 58.2 (C3), 53.9 (C11'), 45.6 (C19 or C19'), 45.5 (C19 or C19'), 39.6 
(C12), 28.4 (C17'), 27.9 (C17), 26.5 (C12'), 23.1 (C18'), 22.8 (C18). FTIR (thin film) cm–1: 
3472 (br-m), 2956 (w), 1716 (s), 1668 (s), 1479 (m), 1401 (m). HRMS (ESI) (m/z): calc’d 
for C48H45N6O8 [M+H]+: 833.3293, found: 833.3286. [α]D24: –128 (c = 0.24, CH2Cl2). TLC 
(70% acetone in hexanes), Rf: 0.24 (UV, CAM).  
meta-(−)-Nin,Nin'-Dicarboxybenzyl iso-Naseseazine C (15): 1H NMR (MHz, CDCl3, 20 
ºC): δ 8.19 (br-s, 1H, C8'H), 7.73 (br-s, 1H, C8H), 7.50 (s, 1H, C2'H), 7.48–7.38 (m, 6H, 
PhCbz-H), 7.38–7.34 (m, 2H, C5'H, PhCbz-H), 7.34–7.26 (m, 4H, C7H, PhCbz-H), 7.19 (d, J 
= 7.5 Hz, 1H, C5H), 7.08 (d, J = 7.5 Hz, 1H, C6'H), 7.07–7.02 (m, 1H, C6H), 6.64 (s, 1H, 
C2H), 5.57 (s, 1H, N10'H), 5.41 (d, J = 12.3 Hz, 1H, PhCbzCHa), 5.39 (app-s, 2H, 
PhCbz'CH2), 5.28 (d, J = 12.3 Hz, 1H, PhCbzCHb), 4.29 (dd, J = 2.9, 10.2 Hz, 1H, C11'H), 
4.18–4.14 (m, 1H, C11H), 4.14–4.08 (m, 1H, C15'H), 4.05 (app-t, J = 8.0 Hz, 1H, C15H), 
3.67–3.50 (m, 5H, C12'Ha, C19H, C19'H), 3.15 (dd, J = 5.8, 12.9 Hz, 1H, C12Ha), 2.92–
2.81 (m, 2H, C12Hb, C12'Hb), 2.37–2.28 (m, 2H), 2.27–2.15 (m, 1H, C17'H), 2.11–1.98 (m, 
3H, C17Hb, C18H), 1.98–1.85 (m, 2H, C18'H). 13C NMR (MHz, CDCl3, 20 ºC): δ 169.4 
(C16'), 166.0 (C16), 165.4 (C13), 165.0 (C13'), 153.1 (CCbz=O), 150.3 (CCbz'=O), 141.5 (C9), 
138.8 (C7'), 136.2 (2C, C4', PhCbz-i-C), 134.9 (3C, C4, C9', PhCbz'-i-C), 129.3 (C7), 129.0 
(2C, PhCbz-C), 128.8 (PhCbz-C), 128.6 (PhCbz-C), 128.3 (PhCbz-C), 128.2 (PhCbz-C), 124.8 
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(C2'), 124.7 (C7'), 124.0 (C5), 121.1 (C6), 119.5 (C5'), 117.6 (C8), 115.7 (C3'), 113.0 (C8'), 
81.8 (C2), 69.1 (PhCbz'-CH2), 68.3 (PhCbz-CH2), 60.7 (C11 or C15'), 60.6 (C11 or C15'), 59.3 
(C15), 58.6 (C3), 54.0 (C11'), 45.6 (C19 or C19'), 45.5 (C19 or C19'), 39.4 (C12), 28.4 (C17'), 
28.0 (C17), 26.5 (C12'), 23.1 (C18'), 22.7 (C18). FTIR (thin film) cm–1: 3472 (br-m), 2955 
(w), 1713 (s), 1667 (s), 1480 (m), 1398 (m). HRMS (ESI) (m/z): calc’d for C48H45N6O8 
[M+H]+: 833.3293, found: 833.3278. [α]D24: –166 (c = 0.26, CHCl3). TLC (70% acetone 
in hexanes), Rf: 0.28 (UV, CAM). 





(−)-Naseseazine C (4): Palladium on activated charcoal (3.3 mg, 3.1 µmol, 20 mol%) 
was added to a solution of para(−)-Nin,Nin'-dicarboxybenzyl naseseazine C 14 (12.9 mg, 
30.4 mmol, 1 equiv) in degassed (N2 stream, 5 min) ethanol (1.6 mL). A stream of 
hydrogen gas was passed through the heterogeneous mixture for 2 min by discharge of 
a balloon equipped with a needle extending into the reaction mixture. After stirring the 
reaction mixture at 22 °C for 21 h under an atmosphere of hydrogen gas, the solution 
was degassed (N2 stream, 5 min) and filtered through Celite. The filter cake was 
washed with methanol (3 × 2 mL) and the combined filtrates were concentrated under 
reduced pressure. The crude reaction mixture was purified by flash column 
chromatography on silica gel (eluent: 70→ 90% acetone in dichloromethane) to afford 
(–)-4 (7.0 mg, 80%). Structural assignments were made using additional information 
from gCOSY, HSQC, HMBC and nOe experiments. 1H NMR (MHz, CD3OD, 20 ºC): δ 
7.64 (d, J = 1.8 Hz, 1H, C5'H), 7.24 (d, J = 8.6 Hz, 1H, C8'H), 7.19 (d, J = 7.4 Hz, 1H, 
C5H), 7.13 (dd, J = 1.9, 8.6 Hz, 1H, C7'H), 7.08 (s, 1H, C2'H), 7.06 (td, J = 1.2, 7.6 Hz, 
1H, C7H), 6.75 (td, J = 1.0, 7.5 Hz, 1H, C6H), 6.71 (d, J = 8.1 Hz, 1H, C8H), 5.70 (s, 1H, 
C2H), 4.39 (td, J = 1.8, 4.9 Hz, 1H, C11'H), 4.31–4.23 (m, 2H, C11H, C15H), 3.97 (ddd, J = 
1.9, 6.4, 10.9 Hz, 1H, C15'H), 3.54–3.47 (m, 2H, C19H), 3.45–3.39 (m, 1H, C19'Ha), 3.28 
(app-d, J = 5.2 Hz, 2H, C12'H), 3.26–3.21 (m, 1H, C19'Hb), 3.12 (dd, J = 6.1, 12.7 Hz, 1H, 
C12Ha), 2.95–2.88 (m, 1H, C12Hb), 2.33–2.25 (m, 1H, C17Ha), 2.10–2.00 (m, 2H, C17Hb, 
C18Ha), 1.98–1.87 (m, 2H, C17'Ha, C18Hb), 1.71–1.60 (m, 1H, C18'Ha), 1.48–1.40 (m, 1H, 

















































(–)-14 (–)-naseseazine C (4)
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N1'H), 7.74 (s, 1H, N10'H), 7.63 (s, 1H, C5'H), 7.22, (d, J = 8.6 Hz, 1H, C8'H), 7.17 (s, 1H, 
C8'H), 7.16 (d, J = 8.7 Hz, 1H, C5H), 7.03 (d, J = 8.6 Hz, 1H, C7'H), 6.98 (app-t, J = 7.7 
Hz, 1H, C7H), 6.65 (d, J = 8.6 Hz, C8H), 6.64 (s, 1H, N1H), 6.61 (app-t, J = 7.4 Hz, 1H, 
C6H), 5.63 (s, 1H, C2H), 4.35–4.27 (m, 2H, C11'H, C15H), 4.16 (dd, J = 6.1, 11.4 Hz, 1H, 
C11H), 4.09 (app-t, J = 8.4 Hz, 1H, C15'H), 3.45–3.33 (m, 3H, C19H, C19'Ha), 3.33–3.23 
(m, 1H, C19'Hb), 3.22 (dd, J = 4.8, 14.9 Hz, 1H, C12'Ha), 3.10–3.02 (m, 2H, C12Ha, 
C12'Hb), 2.68 (app-t, J = 12.0 Hz, 1H, C12Hb), 2.19–2.08 (m, 1H, C17Ha), 2.04–1.97 (m, 
1H, C17'Ha), 1.97–1.86 (m, 2H, C17Hb, C18Ha), 1.85–1.76 (m, 1H, C18Hb), 1.75–1.68 (m, 
1H, C18'Ha), 1.68–1.59 (m, 1H, C18'Hb), 1.53–1.42 (m, 1H, C17'Hb). 13C NMR (MHz, 
CD3OD, 20 ºC): δ 170.7 (C16'), 168.5 (C16), 168.0 (C13), 167.4 (C13'), 150.6 (C9), 136.9 
(C9'), 135.3 (C6'), 134.2 (C4), 129.6 (C7), 128.5 (C4'), 126.2 (C2'), 125.2 (C5), 121.1 (C7'), 
120.5 (C6), 116.3 (C5'), 112.6 (C8'), 111.1 (C8), 109.9 (C3'), 83.6 (C2), 61.9 (C15), 61.7 
(C11), 60.8 (C3), 60.0 (C15'), 57.2 (C11'), 46.3 (C19), 46.0 (C19'), 41.1 (C12), 29.1 (2C, C12', 
C17'), 28.9 (C17), 23.8 (C18), 22.6 (C18'). 13C NMR (MHz, DMSO-d6, 20 ºC)1: δ 169.2 
(C16'), 166.0 (C16), 165.6 (C13'), 165.3 (C13), 149.3 (C9), 134.8 (C9'), 134.1 (C6'), 133.0 
(C4), 128.1 (C7), 127.1 (C4'), 124.8 (C2'), 123.8 (C5), 119.2 (C7'), 118.1 (C6), 114.6 (C5'), 
111.4 (C8'), 109.6 (C3'), 109.5 (C8), 81.1 (C2), 60.1 (C11), 59.7 (C15), 58.7 (C3), 58.5 
(C15'), 55.1 (C11'), 44.7 (2C, C19, C19'), 39.9 (C12), 27.7 (C17'), 27.4 (C17), 25.4 (C12'), 22.6 
(C18), 22.0 (C18'). FTIR (thin film) cm–1: 3310 (br-m), 2926 (m), 1661 (s), 1435 (s), 
1301 (w), 1150 (w). HRMS (ESI) (m/z): calc’d for C32H33N6O4 [M+H]+:565.2558, found: 
565.2551. [α]D24: –180 (c = 0.16, CH3OH).2 TLC (80% acetone in dichloromethane), Rf: 
0.11 (UV, CAM). 
 





(−)-iso-Naseseazine C (16): Palladium on activated charcoal (6.5 mg, 6.1 µmol, 20.0 
mol%) was added to a solution of meta(−)-Nin,Nin'-dicarboxybenzyl iso-naseseazine C (–
)-15 (25.2 mg, 30.3 µmol, 1 equiv) in degassed (N2 stream, 5 min) ethanol (3 mL). A 
stream of hydrogen gas was passed through the heterogeneous mixture for 2 min by 
discharge of a balloon equipped with a needle extending into the reaction mixture. After 
stirring the reaction mixture at 22 °C for 64 h under an atmosphere of hydrogen gas, the 
solution was degassed (N2 stream, 5 min) and filtered over Celite. The filter cake was 
washed with methanol (3 × 2 mL) and the combined filtrates were concentrated under 
reduced pressure. The crude reaction mixture was purified by flash column 
chromatography on silica gel (eluent: 70→ 90% acetone in dichloromethane) to afford 
(–)-8 (14.3 mg, 83.6%). Structural assignments were made using additional information 
from gCOSY, HSQC, HMBC and nOe experiments. 1H NMR (MHz, CD3OD, 20 ºC): δ 
7.49 (d, J = 8.4 Hz, 1H, C5'H), 7.31 (d, J = 1.6 Hz, 1H, C8'H), 7.11 –7.01 (m, 2H, C5H, 
C6'H), 7.06 (s, 1H, C2'H), 7.05 (td, J = 1.1, 7.1 Hz, 1H, C7H), 6.72 (td, J = 1.0, 7.5 Hz, 
1H, C6H), 6.70 (d, J = 7.7 Hz, 1H, C8H), 5.64 (s, 1H, C2H), 4.35 (td, J = 1.8, 5.0 Hz, 1H, 
C11'H), 4.21–4.15 (m, 2H, C11H, C15H), 3.92 (ddd, J = 1.9, 6.5, 11.0 Hz, 1H, C15'H), 
3.54–3.44 (m, 2H, C19H), 3.44–3.37 (m, 1H, C19'Ha), 3.26 (app-d, J = 4.5 Hz, 2H, C12'H), 
3.24–3.19 (m, 1H, C19'Hb), 3.05 (dd, J = 6.0, 12.6 Hz, 1H, C12Ha), 2.85–2.78 (m, 1H, 
C12Hb), 2.29–2.21 (m, 1H, C17Ha), 2.08–1.97 (m, 2H, C17Hb, C18Ha), 1.95–1.85 (m, 2H, 
C17'Ha, C18Hb), 1.67–1.56 (m, 1H, C18'Ha), 1.46–1.30 (m, 1H, C18'Hb), 0.96–0.86 (m, 1H, 
















































(–)-15 (–)-iso-naseseazine C (16)
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N10'H), 7.50 (d, J = 8.4 Hz, 1H, C5'H), 7.23 (d, J = 1.6 Hz, 1H, C8'H), 7.17 (d, J = 7.4 Hz, 
1H, C5H), 7.15 (d, J = 2.4 Hz, 1H, C2'H), 7.08 (dd, J = 1.8, 8.3 Hz, 1H, C6'H), 6.99 (app-t, 
J = 7.8 Hz, 1H, C7H), 6.65 (d, J = 4.7 Hz, 1H, C8H), 6.65 (s, 1H, N1H), 6.63 (d, J = 7.5 
Hz, 1H, C6H), 5.56 (s, 1H, C2H), 4.31 (ddd, J = 1.8, 6.9, 9.1 Hz, 1H, C15H), 4.26 (app-t, 
J = 5.3 Hz, 1H, C11'H), 4.17 (ddd, J = 3.2, 6.6, 10.1 Hz, 1H, C11H), 4.05 (dd, J = 6.9, 9.7 
Hz, 1H, C15'H), 3.45–3.30 (m, 3H, C19'Ha, C19H), 3.25 (td, J = 4.3, 7.7, 8.3 Hz, 1H, 
C19'Hb), 3.20 (app-dd, J = 4.9, 15.0 Hz, 1H, C12'Ha), 3.03 (app-ddd, J = 6.1, 13.8, 21.2 
Hz, 2H, C12'Hb, C12Ha), 2.70–2.61 (m, 1H, C12Hb), 2.19–2.07 (m, 1H, C17'Ha), 2.01–1.86 
(m, 3H, C17H, C18Ha), 1.86–1.73 (m, 1H, C18Hb), 1.73–1.63 (m, 1H, C18'Ha), 1.63–1.56 
(m, 1H, C18'Hb), 1.46–1.35 (m, 1H, C17'Hb). 13C NMR (MHz, CD3OD, 20 ºC): δ 170.8 
(C16'), 168.5 (C16), 168.0 (C13), 167.4 (C13'), 150.6 (C9), 138.2 (C7'), 137.9 (C9'), 133.8 
(C4), 129.7 (C7), 127.6 (C4'), 126.1 (C2'), 125.1 (C5), 120.4 (C5' or C6), 120.3 (C5' or C6), 
118.0 (C6'), 111.1 (C8), 109.5 (C3'), 109.3 (C8'), 83.5 (C2), 61.8 (C11), 61.6 (C15), 60.7 
(C3), 60.0 (C15'), 57.1 (C11'), 46.3 (C19), 46.0 (C19'), 40.9 (C12), 29.1 (C12' or C17'), 29.0 
(C12' or C17'), 28.8 (C17), 23.8 (C18), 22.5 (C18'). 13C NMR (MHz, DMSO-d6, 20 ºC): δ 
169.1 (C16'), 166.1 (C16), 165.5 (C13'), 165.3 (C13), 149.4 (C9), 136.8 (C7'), 135.9 (C9'), 
132.4 (C4), 128.2 (C7), 126.1 (C4'), 124.8 (C2'), 124.0 (C5), 119.0 (C5'), 118.1 (C6), 116.4 
(C6'), 109.5 (C8), 109.2 (C3'), 108.0 (C8'), 81.5 (C2), 60.2 (C11), 59.6 (C15), 58.8 (C3), 58.4 
(C15'), 55.2 (C11'), 44.8 (C19 or C19'), 44.6 (C19 or C19'), 39.9 (C12), 27.6 (C17'), 27.4 (C17), 
25.7 (C12'), 22.6 (C18), 21.9 (C18'). FTIR (thin film) cm–1: 3310 (br-m), 2955 (w), 1653 (s), 
1457 (m), 1340 (w), 1056 (w). HRMS (ESI) (m/z): calc’d for C32H33N6O4 [M+H]+: 
565.2558, found: 565.2554. [α]D24: –312 (c = 0.42, CH3OH).3 TLC (80% acetone in 
dichloromethane), Rf: 0.11 (UV, CAM). 
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Supplementary Table 2-4. Comparison of our 1H NMR data for synthetic (–)-
naseseazine C (4) and (–)-iso-naseseazine C (16) as well as biocatalytic (–)-










(–)-naseseazine C (4) 
1H NMR, 500 MHz, 





1H NMR, 500 MHz, 





1H NMR, 600 
MHz, CD3OD 
N1 – – – – 
C2 5.71 (s) 5.70 (s) 5.64 (s) 5.76 (s) 
C3 – – – – 
C4 – – – – 
C5 
7.19 (d, J = 7.5 
Hz) 
7.19 (d, J = 7.4 Hz) 7.11–7.01 (m) 
7.15 (d, J = 7.7 
Hz) 
C6 
6.76 (dt, J = 0.8, 
7.5 Hz) 
6.75 (td, J = 1.0, 7.5 
Hz) 
6.72 (td, J = 1.0, 7.5 
Hz) 
6.71 (t, J = 7.5 
Hz) 
C7 
7.07 (dt, J = 1.1, 
7.5 Hz) 
7.06 (td, J = 1.2, 7.6 
Hz) 
7.05 (td, J = 1.1, 7.1 
Hz) 
7.03 (td, J = 
1.3, 7.7 Hz) 
C8 
6.72 (d, J = 7.8 
Hz) 
6.71 (d, J = 8.1 Hz) 6.70 (d, J = 7.7 Hz) 
6.68 (d, J = 7.9 
Hz) 
C9 – – – – 
N10 – – – – 
C11 
4.32 (app-t, J = 
11.4 Hz) 
4.31–4.23 (m) 4.21–4.15 (m) 
4.27 (td, J = 
2.0, 8.4 Hz) 
C12 
2.94 (app-t, J = 
11.4 Hz) 
3.12 (dd, J = 
6.2, 12.6 Hz) 
2.95–2.88 (m) 
3.12 (dd, J = 6.1, 
12.7 Hz) 
2.85–2.78 (m) 
3.05 (dd, J =6.0, 
12.6 Hz) 
2.89 (dd, J = 
11.2, 12.7 Hz) 
3.09 (dd, J = 
6.0, 12.7 Hz ) 
C13 – – – – 
N14 – –  – 
C15 4.28 (app-t, J 4.31–4.23 (m) 4.21–4.15 (m) 4.24–4.21 (m) 																																																								
7 The comparison of the 1H and 13C NMR chemical shifts of the reported “new (–)-iso-naseseazine B” with both synthetic 
regioisomers (–)-7 and (–)-8 in CD3OD shows that the data for “new (–)-iso-naseseazine B” is most consistent with synthetic (–)-
naseseazine C (7). 























C19 3.52 (m) 3.54–3.47 (m) 3.54–3.44 (m) 3.52–3.45 (m) 
N1' – – – – 
C2' 7.09 (s) 7.08 (s) 7.06 (s) 7.05 (s) 
C3' – – – – 
C4' – – – – 
C5' 
7.24 (d, J = 8.6 
Hz) 
7.64 (d, J = 1.8 Hz)8  7.49 (d, J = 8.4 Hz) 
7.60 (d, J = 1.8 
Hz) 
C6' 
7.12 (dd, J = 
1.6, 8.6 Hz) 
–13 7.11–7.01 (m) –13 
C7' – 
7.13 (dd, J = 1.9, 8.6 
Hz)13  
– 
7.09 (dd, J = 
1.8, 8.5 Hz) 
C8' 
7.64 (d, J = 1.3 
Hz) 
7.24 (d, J = 8.6 Hz)13  7.31 (d, J = 1.6 Hz) 
7.21 (d, J = 8.6 
Hz) 
C9' – – – – 
N10' – – – – 
C11' 
4.40 (br-t, J = 
4.8 Hz) 
4.39 (td, J = 1.8, 4.9 
Hz) 
4.35 (td, J = 1.8, 5.0 
Hz) 
4.36 (td, J = 
1.7, 5.0 Hz) 
C12' 3.33 (m) 
3.28 (app-d, J = 5.2 
Hz) 
3.26 (app-d, J = 4.5 
Hz) 
3.25 (d, J = 5.1 
Hz) 
C13' – – – – 
N14' – – – – 
C15' 
3.97 (ddd, J = 
1.5, 6.4, 10.8 
Hz) 
3.97 (ddd, J = 1.9, 
6.4, 10.9 Hz) 
3.92 (ddd, J = 1.9, 
6.5, 11.0 Hz) 
3.94 (ddd, J = 
1.8, 6.4, 11.0 
Hz) 



















8 Our assignments of these resonances are supported by key HSQC and HMBC correlations. 
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9 The comparison of the 1H and 13C NM
R chemical shifts of the reported “new (–)-iso-naseseazine B” with both synthetic regioisomers (–)-7 and (–)-8 in CD
3 OD shows that the 
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11 The comparison of the 1H and 13C NM
R chemical shifts of the reported “new (–)-iso-naseseazine B” with both synthetic regioisomers (–)-7 and (–)-8 in CD
3 OD shows that the 
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Supplementary Table 2-7. Comparison of our 1H NMR data for (–)-naseseazine C 




naseseazine C  
1H NMR, 800 MHz, 
DMSO-d6 
This Work 
(–)-naseseazine C (4) 
1H NMR, 500 MHz, DMSO-d6, 
20 ºC 
This Work 
(–)-iso-naseseazine C (16) 
1H NMR, 500 MHz, DMSO-d6, 
20 ºC 
N1 6.56 (s) 6.64 (s) 6.65 (s) 
C2 5.62 (s) 5.63 (s) 5.56 (s) 
C3 – – – 
C4 – – – 
C5 
7.16 (dd, J = 1.2, 
7.4 Hz) 
7.16 (d, J = 8.7 Hz) 7.17 (d, J = 7.4 Hz) 
C6 
6.61 (td, J = 1.0, 7.4 
Hz) 
6.61 (app-t, J = 6.4 Hz) 6.63 (d, J = 4.7 Hz) 
C7 
6.98 (td, J = 1.2, 7.7 
Hz) 
6.98 (app-t, J = 7.7 Hz) 6.99 (app-t, J = 7.8 Hz) 
C8 
6.65 (dd, J =1.5, 7.8 
Hz) 
6.65 (d, J = 8.6 Hz) 6.65 (d, J = 4.7 Hz) 
C9 – – – 
N10 – – – 
C11 4.16 (m) 4.16 (dd, J = 6.1, 11.4 Hz) 





2.68 (app-t, J = 12.0 Hz) 
3.10–3.02 (m) 
2.70–2.61 (m) 
3.03 (app-ddd, J = 6.1, 13.8, 
21.2 Hz) 
C13 – – – 
N14 – – – 
C15 4.29 (t) 4.35–4.27 (m) 
4.31 (ddd, J = 1.8, 6.9, 9.1 
Hz) 
C16 – – – 
C17 1.94 (m) 1.97–1.86 (m) 2.01–1.86 (m) 																																																								
12 The comparison of the 1H and 13C NMR chemical shifts of the reported naseseazine C with both synthetic regioisomers (–)-7 
and (–)-8 in DMSO-d6 shows that the data for naseseazine C is most consistent with synthetic (–)-naseseazine C (7). 
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3.45–3.33 (m) 3.45–3.30 (m) 
N1' 10.82 (d, J =2.4 Hz) 10.84 (s) 10.79 (d, J = 2.5 Hz) 
C2' 7.17 (d, J = 2.4 Hz) 7.17 (s) 7.15 (d, J = 2.4 Hz) 
C3' – – – 
C4' – – – 
C5' 7.62 (d, J = 1.8 Hz) 7.63 (s) 7.50 (d, J = 8.4 Hz) 
C6' – – 7.08 (dd, J = 1.8, 8.3 Hz) 
C7' 
7.03 (dd, J = 1.8, 
8.5 Hz) 
7.03 (d, J = 8.6 Hz) – 
C8' 7.22 (d, J = 8.5 Hz) 7.22 (d, J = 8.6 Hz) 7.23 (d, J = 1.6 Hz) 
C9' – – – 
N10' 7.70 (s) 7.74 (s) 7.68 (s) 





3.22 (dd, J = 4.8, 14.9 Hz) 
3.03 (app-ddd, J = 6.1, 13.8, 
21.2 Hz) 
3.20 (app-dd, J = 4.9, 15.0 
Hz) 
C13' – – – 
N14' – – – 
C15' 4.08 (m) 4.09 (app-t, J = 8.4 Hz) 4.05 (dd, J = 6.9, 9.7 Hz) 
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13 The comparison of the 1H and 13C NM
R chemical shifts of the reported naseseazine C with both synthetic regioisomers (–)-7 and (–)-8 in DM
SO-d
6  shows that the data for 
naseseazine C is most consistent with synthetic (–)-naseseazine C (7). 
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15 The comparison of the 1H and 13C NM
R chemical shifts of the reported naseseazine C with both synthetic regioisomers (–)-7 and (–)-8 in DM
SO-d
6  shows that the data for 
naseseazine C is most consistent with synthetic (–)-naseseazine C (7). 
16 W
e do not observe signals at 145.9, 125.8, and 110.4 ppm in our data, which has an excellent signal-to-noise ratio. 
17 W
e observe signals at 133.0, 123.8, and 109.5 ppm in our 13C NM
R spectrum, which has an excellent signal-to-noise ratio. 
18 W






















































































44.8 or 44.6 
0 
0.1 or –0.1 
44.7 
44.7 
44.8 or 44.6 
0 
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20 Buedenbender, L.; Grkovic, T.; Duffy, S.; Kurtbotke, D. I.; Avery, V. M
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5.84 (s)  











6.83 (d, J = 7.2)  
6.82 (d, J = 7.2)  
C
6 
6.68 (app-t, J = 7.3)  
6.67 (app-t, J = 7.3)  
C
7 
7.06 (app-dt, J = 1.2, 7.9)  
7.04 (app-dt, J = 1.2, 7.9)  
C
8 
6.69 (d, J = 7.7)  











4.71 (app-t, J = 8.6)  




) 2.57 (dd, J = 10.2, 
13.7)  
3.44 (m











4.29 (app-t, J = 7.7)  

































7.12 (s)  











7.57 (d, J = 7.4)  
7.56 (d, J = 7.4)  
C
6 
7.01 (dd, J = 1.6, 8.5)  







7.41 (d, J =1.3)  











4.39 (app-t, J = 4.6)  


















3.98 (ddd, J = 1.4, 6.3, 10.7) 
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Chapter 3 
Evaluation of Substrate Flexibility of Bacterial DKP Dimerases NascB 




 In this chapter we explore substrate flexibility of diketopiperazine dimerizing 
cytochromes P450, NascB and NznB described in Chapter 2. A small library of 
diketopiperazines was synthesized to profile the initial reactivity of NascB and NznB 
against non-native substrates. NascB and NznB were unable to homodimerize 
diketopiperazines with sterically bulky amino acid side chains (Leu, Phe, Tyr, Trp), and 
a bioinformatics campaign in an effort to discover homologues with new or broader 
selectivity was undertaken. This campaign resulted in the discovery of two cytochromes 
with new selectivity, NascB-F5053 (from Streptomyces sp. NRRL-F5055) whose native 
reaction generated a mixture of (–)-naseseazine C (1) and (–)-aspergilazine A (2), and 
NascB-S1868 (from Streptomyces sp. NRRL-S1868) which formed (–)-aspergilazine A 
(2) exclusively. All four cytochromes were screened for their dimerization potential 
against a library of > 30 diketopiperazines, and a biotransformation approach was 
developed to scale reactions which form unique dimeric products. This work was 
enabled through a joint effort from myself, Dr. Yogan Khatri who assisted in design of 




The biological activity of diketopiperazine dimers has inspired the development of 
efficient methods towards the total synthesis of this class of compounds. While these 
methods have enabled the synthesis of many of the compounds, there are no general 
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methods that allow for the synthesis of a variety of stereochemistries or 
connectivities from the same starting materials. Because of this, it is particularly 
challenging to generate libraries of these compounds, identify key pharmacophores and 
identify structure activity relationships within the molecular architecture. NascB and 
NznB are both site- and stereodivergent cytochromes, and from the same 
diketopiperazine monore generate two stereochemically, regiochemically, and 
topologically different dimeric structures. 
Based on the flexibility displayed in the in vitro simulation of biosynthetic 
crosstalk seen in Chapter 1, we expected that both NascB and NznB may be able to 
catalyze the dimerization of a variety of DKP substrates and could be used to 
biocatalytically generate a library of different homo- and heterodimeric structures. The 
orthogonality of certain functional groups to biological reactions such as alkynes also 
act as functional handles for late stage diversification of dimers, and we sought to 
evaluate the ability for NascB and NznB to incorporate these functional groups into 
dimeric scaffolds for secondary diversification of these scaffolds. 
 
3.3 Research and Discussion 
To screen the reactivity profile of NascB and NznB, a small library of 
diketopiperazines were synthesized in three steps with no intermittent purification 
(Experimental). This set of substrates was screened against both the NascB and NznB 
cytochromes P450 for their ability to homodimerize under conditions optimized to fully 
convert native substrate 4 with the lowest loading of NascB biocatalyst. However in 
nearly all cases these reactions could be pushed to complete conversion with increased 




Figure 3-1. Percent conversions of homodimerizations catalyzed by NascB and NznB. 
 
NascB consistently showed higher conversions at equivalent concentrations to 
NznB, and we hypothesize that this is due to the stability of this catalyst, as NznB is 
more sensitive to denaturation during purification and can be seen precipitating under 
reaction conditions. Notably, the alkynyl diketopiperazine 11 was accepted as a 
substrate and was readily converted to a dimeric product and we are currently 
evaluating further functionalization of these dimeric products in copper-catalyzed [3+2] 
azide-alkyne cycloaddition “click” reactions. 1 C6-fluorinated substrate 38 was converted 
by NascB and completely stopped reactivity for NznB, as C6 is the site for dimerization. 
Substrates with bulkier amino acid side chains, 18, 20, 21 and 23, consistently showed 
little to no conversion to dimeric products. Based on the cyclic nature of native substrate 
4, and minimal steric bulk of native substrate 5, we hypothesized that the enzyme active 
site was not evolved to recognize amino acids with these bulky side chains. 
 
3.3.1 Bioinformatic Discovery and in vitro analysis of NascB homologues 
Dimerization of large substrates (18, 20, 21, and 23) failed, and in hopes of 
































































































































































































































the NCBI database for homologues of cytochromes NascB and NznB. To identify 
NascB/NznB homologues, we used their upstream CDPSs, NascA and NznB, well as all 
known CDPS-driven gene clusters and using BLASTp2 we identified the top 100 
homologues for each CDPS, and then eliminated duplicates by hand. This curated 
CDPS library of 489 members was then used to assemble a sequence similarity 
network (SSN) 3 and group CDPS-driven clusters with their respective 
reactivity/metabolites and predictively identify NascB and NznB homologues.  
 
 
Figure 3-2. Curated Sequence Similarity Network (SSN) of 498 CDPS with products from characterized biosynthetic 
gene clusters above each cluster. 
 
Analysis of the SSN identified two Streptomyces strains deposited in the NRRL 
(NRRL-F5053 and NRRL-S1868) both of which possessed NascB (hereon refered to as 
NascB-CMB-MQ030) homologues 87% and 84% identity respectively. These strains 
were obtained from the NRRL, genomic DNA harvested and the NascB homologues 
	 100	
NascB-F5053 and NascB-S1868 were cloned, expressed and their substrate scope 
characterized. NznB homologues from these strains were also identified, however these 
NznB homologues had extremely high sequence homology (99% identity) and as such 
we hypothesized they had similar reactivities and selectivities and these cytochromes 
were not explored further.  
 
 
Figure 3-3. Sequence alignment of NascB homologues from NRRL-F5053 and NRRL-S1868.  
 
3.3.3 Expression and Characterization of NascB Homolgoues 
When subjected to reaction conditions optimized for NascB-CMB-MQ030 and 4, 
NascB-F5053 generated (–)-naseseazine C (1) as the major product produced along 
with a less polar minor product whose mass also corresponded to a dimer. When this 
reaction was performed with NascB-S1868 this new product, 2, was produced 
exclusively. To identify this product, this reaction was scaled up (10mg) and major 
product purified by HPLC. NMR characterization of this product revealed there was no 
distinctive aminal proton corresponding to a cyclized dimer. When NMR solvent was 
exchanged to DMSO-d6 the spectra corresponded favorably to reported spectra from 
both isolation and total synthesis reports for uncyclized, unsymmetrical homodimer (–)-




Figure 3-4. HPLC traces showing conversion of 4 by NascB_CMB-MQ030, NascB-F5053, and NascB-S1868. 
 
While initially isolated from a fungal source,7 (–)-aspergilazine A (2) is among a 
rare class of natural products to be isolated from both a fungal and bacterial5 source. 
The bacterial isolation report of 2 from Streptomyces sp. SMA-1 also reports the co-
isolation of (+)-naseseazine B (3) and (–)-naseseazine C (1) (incorrectly assigned as 
“isonaseseazine B”). Strain NRRL-F5053 possesses an NznB homologue, and as seen 
in Figure 3-4, NascB-F5053 generates both (–)-naseseazine C (1) as well as (–)-
aspergilazine A (3), and possesses the biosynthetic potential to produce all three of 
these metabolites suggesting that NRRL-F5053 is likely a close relative to this 
Streptomyces sp. SMA-1.  
 
 

















































Given the change in chemoselectivity between intermolecular Csp3–Csp2 bond 
formation catalyzed by NascB-CMB-MQ030, and intermolecular Csp2–Nsp2 bond 
formation seen in reactions with NascB-F5053 and NascB-S1868, we hypothesized that 
NascB-F5053 and NascB_S1868 may possess different selectivities in terms of their 
substrate scope. To examine this, the initial set of substrates used to profile NascB-




Figure 3-6. Grouped bar graph representation of percent conversions from reaction of homodimerization substrates 
with NascB-CMB-MQ030, NznB, NascB-F5053 and NascB-S1868. Each entry is the result of 3 reactions with 
standard deviation shown. 
 
In this homodimerization assay, NascB-F5053 and NascB-S1868 consistently 
catalyze higher conversions of all substrates compared to NascB-CMB-MQ030 and 
NznB. Examination of the HPLC traces of these reactions reveal that not only do 
NascB-F5053 and NascB-S1868 have increased activity, but these cytochromes also 
generate an increased number of products in many cases. Homodimerization of 9 by 
NascB-F5053 and NascB-S1868 leads to formation of an additional product, and each 




Figure 3-7. HPLC traces showing differential product profiles for reaction of 9 with NascB-CMB-MQ030, NascB-
F5053, NascB-S1868, and NznB. 
 
To further profile this differential reactivity, a larger subset of DKP substrates 
were synthesized and subjected to a heterodimerization reaction conditions with 4 as 
the common monomer to all reactions (Figure 8). 
 
3.3.4 Heterodimerization Substrate Scope of NascB-CMB-MQ030, NascB-F5053, 
NascB-S1868, and NznB. 
The majority of known diketopiperazine dimers are composed of a dimerization of 
two units of the same diketopiperazine.8 There are several examples of isolated DKP 
dimers, which are the result of a heterodimerization of two different diketopiperazine 
monomers,9-11 including the initial isolation report of the (+)-naseseazines, as (+)-
naseseazine A is a non-symmetrical heterodimer of 4 and 5. To explore the potential of 
NascB-CMB-MQ030, NascB-F5053, NascB-S1868, and NznB to heterodimerize two 
diketopiperazines, a library of over 30 members were constructed and were subjected 
to heterodimerization reactions with native substrate 4 (Figure 3-8). 
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Figure 3-8. Full panel of diketopiperazines synthesized and assayed by cytochromes. 
 
Many of these reactions resulted in the formation of complex mixtures, as many 
of the DKP substrates have very similar polarity, in many cases starting materials were 
not fully consumed. Each substrate is capable of generating at least one homodimer, 
and multiple isomeric heterodimers can be formed, all of which have relatively similar 
polarity. Regardless of HPLC column selection, solvent, pH, and method development, 
in the majority of reactions substrates and/or products co-eluted and did not allow for 









































































































































































































































































































































Figure 3-9. Representative HPLC traces from heterodimerization of 4 and 22, percent conversion cannot be 
calculated for reactions such as these due to co-eluting of substrates and products. 
 
To obtain a general understanding of the substrate selectivity for each enzyme, 
we opted to pursue a binary approach to detecting the formation of heterodimers using 
mass spectrometry summarized in Figure 10. 
Cytochrome 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 
NascB-CMB-MQ030                  
NascB-F5053                  
NascB-S1868                  



























Cytochrome 20 21 22 23 24 25 26 27 28 30 31 32 33 
NascB-CMB-MQ030              
NascB-F5053              
NascB-S1868              
NznB              
Figure 3-10. Binary tables for heterodimerization reactions. Green cells indicate at least one dimer detectable by MS, 
as well as correlating to a new peak in the UV chromatogram, red cells indicate no dimer detected. Orange squares 
are represent sulfur containing dimers which underwent further oxidation from thioether to sulfoxide.  
 
As seen in the homodimerization assay, NascB-F5053 and NascB-S1868 
exhibited increased flexibility substrate flexibility. These cytochromes were more 
capable of generating heterodimers from diketopiperazines with sterically bulky side 
chains (16-20, 23, 28-30, and 33) while NascB-CMB-MQ030 was unable to convert 
these substrates. While conversions were very low for NznB, there were clear dimers 
formed from larger substrates as well. Also of note, 24 inhibited any dimerization from 
occurring (including homodimerization of 4), while 19 did not inhibit dimerization, but 
also did not participate in homo- or heterodimerizations. 
The NascB-F5053 catalyzed heterodimerization reaction of 4 and 23, results in a 
single heterodimeric product, 37 (Figure 3-11), generated exclusively and 
homodimerization of 4 is inhibited and little to no (–)-naseseazine C (1) is observed.  
 
 
Figure 3-11. HPLC trace of NascB-F5053 catalyzed heterodimerization of 4 and 23. 
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Despite their activity in heterodimerization reactions, substrates such as 23 are 
much bulkier, and possess greater degrees of conformational flexibility due to their 
acyclic nature. We hypothesize homodimerization of these substrates is not observed 
due to the inability for the cytochrome P450 active site to accommodate two units of 
these larger substrates in conformations conducive to catalysis. However, as these 
larger monomers are able to selectively form heterodimers with native monomer, 4, 
there must be at least one portion of the binding pocket with the ability to accommodate 
these larger DKP monomers. To gain further insight into this pocket selectivity, we 
strove to scale the heterodimerization of 4 and 23 and characterize the structure of the 
product. However, attempts to scale this reaction in vitro suffered from low, and 
inconsistent conversions. To be able to perform this reaction on a scale that would 
enable resolving the structure of 37 we developed a biotransformation approach that 
would be more amenable to preparatory scale. 
 
3.3.5 Development of a biotransformation platform for scalable synthesis of 
diketopiperazine dimers 
Homo- and heterodimerization substrate scope experiments demonstrated 
biocatalytic potential for NascB-CMB-MQ030 and its homologues to generate a diversity 
of topologically diverse products from a variety of diketopiperazines substrates (Figures 
3-1 and 3-10). Unfortunately many of these reactions generate multiple products, and/or 
suffer from modest to low conversions under optimized in vitro reaction conditions. We 
strove to develop an operationally simple method to scale up these reactions in order to 
access these products for spectroscopic characterization and as a platform to 
synthesize libraries for biological evaluation. Scalability of in vitro reactions is 
troublesome for cytochrome P450 enzymes in particular, as associated electron transfer 
proteins must also be expressed and purified, and in many cases are used, most 
optimally, in stoichiometric excess relative to the cytochrome. Biotransformation has 
been shown to be an effective strategy for biocatalytic oxidation reactions,12-13 and 
circumvents protein purification through co-expression of redox partners (or utilization of 
redox parters native to heterologous host), and feeding substrates directly to a living 
culture. We initially attempted to generate a P450-RhFRED fusion14 for 
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biotransformation, however expression of this chimera resulted exclusively in insoluble 
protein. A two-plasmid system was developed, wherein the plasmid that encodes for 
expression of our P450 of interest is co-transformed with a second a dicistronic plasmid 
which encodes genes for both the S. oleracea ferredoxin (Fdx) and ferredoxin reductase 
(FdR). Both plasmids are co-transformed into E. coli heterologous host C41DE3, and 
protein expression is induced with IPTG. Post induction, cells are washed and 
resuspended in minimal buffer along substrate to be dimerized (Figure 12). 
 
 
Figure 3-12. General biotransformation protocol for DKP dimerization. 
 
Biotransformations using native substrate 4 went to full conversion of substrate to 
product within 5 hours reaction time, and per liter of culture we were able to generate 
10-15 mg of dimeric DKP product using NascB-F5053. The polar diketopiperazine 
monomers and dimers are intransigent to liquid-liquid extraction and result in very low 
recovery from aqueous media directly. Instead, solid phase extraction using XAD-16 
resin was employed, resulting in high extraction efficiency and full recovery of even the 
most polar of DKP products from unwanted media components such as glycerol.  
As noted from heterodimerization reactions, 4 and 23 generated a new single 
heterodimeric product, albeit in low yield and low conversion making it particularly 
unsuitable for in vitro scale up. This reaction was chosen as a test case for 
biotransformation. Under unoptimized conditions, we were able to generate 11 mg of 
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structure of this product as 37. Given the structure of this new product, we propose that 
the pocket that accommodates the southern diketopiperazine has a broader flexibility 
and is able to accommodate larger diketopiperazines in heterodimerization reactions, 




Figure 3-13. HPLC trace of biotransformation of 4 and 23 and structure of product 37. 
 
3.4 Conclusion 
 We synthesized a panel of diketopiperazines and profiled the substrate scope of 
previously described bacterial cytochromes, NascB and NznB, for their enzymatic 
homodimerization activity. In an effort to discover cytochromes with improved or 
divergent reactivity, we probed the NCBI database for putative homologues and 
discovered NascB homologues NascB-F5053 and NascB-S1868. When 4 was 
subjected to reaction conditions with these cytochromes a new metabolite, was 
produced, and when scaled up and characterized the structure of this product was 
determined to be (–)-aspergilazine A (2). A larger series of DKPs were synthesized and 











































 From these heterodimerization reactions we were able to make inferences 
regarding the binding pockets of NascB-F5053, as only a single product was produced 
in the heterodimerization reaction of 4 and 23. As the southern monomer (acceptor) is 
that composed of two bulky tryptohan units (derived from DKP 23), we hypothesize that 
the binding site for this DKP is more flexibile, while the binding pocket for the northern 
monomer (donor) must be more selective for its substrate. 
 
Figure 3-14. Hypothetical representation of binding site where acceptor binding site can accommodate larger 
substrates while donor site is more selective for smaller substrates. 
 
 To efficiently access quantities of material suitable for straightforward 
spectroscopic analysis, a biotransformation approach was developed and implemented 
on the low yielding heterodimerization of 4 and 23, and allowed for 11mg of heterodimer 
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Supplementary Table 3-1. Primers used in cloning NascB-F5053 and NascB-S1868 
Primer 
# 











General procedures for overexpression, purification and spectral characterization 
of cytochrome P450s  
The expression of pET28b-NznB+09 was performed by transforming the plasmid 
into the competent cell E. coli strain C41 (DE3) and selected on Luria-Bertani (LB) 
medium plates containing100 µg/mL kanamycin. A single colony was grown overnight in 
LB broth containing the same concentration of the antibiotics. The main culture was 
prepared by inoculating 1% of each overnight culture into a 2 L baffled flask containing 
500 ml of Terrific Broth (TB) containing 100 µg/mL kanamycin. The cultures were 
incubated at 37°C and 250 rpm for 3-4 h unless the absorbance A590nm = 1. The 
expression of NznB was induced by the addition of 0.8 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and 0.5 mM delta-5-aminolevulinic acid (w/v) as well as 
1mM thiamine. The cultures were incubated further for 30 h, 18°C at 160 rpm. Cells 
were harvested by centrifugation at 5000×g at 4°C for 10 min and the cell pellet was 
stored at –80°C until purification of the protein. 
 
The cell pellet was resuspended in 5% culture volume of lysis buffer (50 mM kPi, 
pH 8.0 containing 200 mM (NH4)2SO4, 20% glycerol, 0.5 mM EDTA, 10 mM beta-
mercaptoethanol and 1mM phenylmethane sulfonyl fluoride (PMSF) and disrupted by 
sonication. The cell lysate was centrifugated (35,000 rpm for 35 min) and filtered (0.2 
µM Millipore filter). The soluble His8-tagged NznB was purified by affinity 
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chromatography using Ni-NTA (Qiagen) column and the collected fractions were 
analyzed by SDS-PAGE. The suitable red fractions were pooled and dialyzed at 4°C 
three times using 50 mM Tris, pH 7.4 containing 50 mM kPi, pH 8.0 containing 200 mM 
(NH4)2SO4, 20% glycerol, 0.5 mM EDTA, and 1 mM dithiothreitol (DTT) against a total of 
6 L buffer. 
 
 UV–Vis spectra for the purified cytochomes were recorded at room temperature 
in buffer (50 mM Tris-HCl buffer, pH 7.4 containing 5% glycerol) was used for the 
spectral measurements of the oxidized and reduced form. NasB was reduced by the 
addition of a small amount of sodium dithionite. The concentration of the P450s was 
estimated by CO-difference spectra, assuming ε(459–490) = 91 mM−1 cm−1 according 
to the method of Omura and Sato.  
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Assembly of Sequence Similarity Network 
The top 100 BlastP hits from the following characterized CDPS were compiled and 
duplicates were removed.
 
Figure S3-1. Natural products from characterized gene clusters and CDPS (in bold) 
used to construct CDPS library and sequence similarity network. 
 
Optimized reaction conditions for analytical scale P450 reactions 
The conversion of DKPs by P450s were carried out with the heterologous redox 
electron partners Fdx and FdR from S. olerecea. The in vitro reaction mixture included 


























B. licheniformis (ATCC 14580)
YvmC-Blic: AAU25020.1
B. subtilis strain 168 
Yvmc-Bsub: AQR87757.1






















































































250 µL. Without exceeding 1% of the total reaction volume, 1mM of DKP dissolved in 
DMSO was added (in the case of heterodimerization reaction, both substrates were 
added to a final concentration of 1mM). The reaction was initiated by adding NADPH (1 
mM). Two of the control reactions including all the contents except for NADPH or P450 
were used as controls. The reaction was incubated at 30°C for 2 h agitating at 600 rpm 
in a thermoshaker (Multi-thermoshaker, Benchmark). Reactions were quenched by the 
addition of 3 volumes of methanol, and centrifuged at 17,000rpm and directly used for 
HPLC analysis. Reactions were resolved using a linear gradient of 15-75% acetonitrile: 
water (0.1% formic acid) over 16 min (2 mL/min flow rate, 40ºC) on a Phenomenex 
Luna 5µ C-18(2) 100A, 250 × 4.60mm 5 micron column. Percent conversions were 
calculated using a 5 point standard curve. 
 
General Procedure for Biotransformation Reactions 
A single colony from a fresh transformation of P450 and sFdx/sFdR plamsid was 
grown overnight in LB broth. The main culture was prepared by inoculating 1% of each 
overnight culture into a 2 L baffled flask containing 500 ml of Terrific Broth (TB) 
containing appropriate antibiotics. The cultures were incubated at 37°C and 250 rpm for 
3-4 h unless the absorbance A590nm = 1. The expression of P450 and electron transfer 
proteins was induced by the addition of 0.8 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and 0.5 mM delta-5-aminolevulinic acid (w/v) as well as 1mM thiamine. The 
cultures were incubated further for 30 h, 18°C at 160 rpm. Cells were harvested by 
centrifugation at 5000×g at 4°C for 10. Pellets were resuspended in a minimal buffer at 
4ºC (50mM kPi (pH = 8.0), and 20% glycerol, 500mL buffer/500mL media) and this was 
repeated 3 times. Pellets were resuspended in a final 500mL of buffer also containing 
100mM EDTA, and substrate(s) were added to a final concentration of 1mM as a 
solution/mixture in 40% β-hydroxycyclodextrin. Reaction was monitored by HPLC until 
no further conversion, and then cells were removed by centrifugation. Media was 
treated with 20g/L of washed XAD-16 resin and incubated overnight with shaking. Resin 
was then removed via filtration and crude product was extracted off of resin by soaking 
resin in 500mL methanol. Methanol wash was then concentrated and residue was 
filtered through celite and directly utilized for purification by prep-HPLC. 
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4: Synthesized via general procedure, 34% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.83 (s, 1H), 7.73 (s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 
7.29 (d, J = 8.1 Hz, 1H), 7.15 (d, J = 2.2 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.93 (t, J = 7.4 
Hz, 1H), 1.94 (dtd, J = 9.8, 6.9, 2.7 Hz, 1H), 1.66 (ddd, J = 19.1, 9.1, 5.6 Hz, 1H), 1.59 
(ddp, J = 12.2, 8.4, 4.6, 4.1 Hz, 1H), 1.35 (dtd, J = 12.1, 10.3, 7.8 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 169.43, 165.92, 136.37, 127.77, 124.82, 121.30, 119.08, 
118.65, 111.65, 109.70, 58.85, 55.66, 45.03, 28.11, 26.23, 22.31.  
 
5: Synthesized via general procedure, 23% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.87 (s, 1H), 8.00 (s, 1H), 7.89 (s, 1H), 7.54 (d, J = 
7.9 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.04 – 6.97 (m, 2H), 6.91 (t, J = 7.4 Hz, 1H), 4.08 









1) EDC (1.0 equiv), HOBt (1.0 equiv), Et3N (1.0 equiv)
































Hz, 1H), 2.98 (dd, J = 14.4, 4.6 Hz, 1H), 2.47 (t, J = 1.9 Hz, 1H), 0.38 (d, J = 7.0 Hz, 
3H). 
 
13C NMR (151 MHz, dmso) δ 168.14, 167.16, 136.20, 128.22, 124.98, 121.22, 119.40, 
118.80, 111.51, 108.91, 55.82, 50.20, 29.27, 19.98. 
 
  6: Synthesized via general procedure, 52% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.84 (s, 1H), 7.97 (s, 1H), 7.85 (d, J = 2.3 Hz, 1H), 
7.57 (d, J = 7.9 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 2.3 Hz, 1H), 6.98 (t, J = 
7.5 Hz, 1H), 6.90 (t, J = 7.4 Hz, 1H), 4.10 (d, J = 2.3 Hz, 1H), 3.51 – 3.34 (m, 1H), 3.18 
(dd, J = 14.4, 5.0 Hz, 1H), 3.04 (dd, J = 14.5, 4.6 Hz, 1H), 2.47 (d, J = 1.9 Hz, 1H), 1.61 
(dtd, J = 14.0, 7.1, 3.8 Hz, 1H), 0.57 (d, J = 7.1 Hz, 4H), 0.13 (d, J = 6.8 Hz, 3H). 
 
13C NMR (151 MHz, dmso) δ 167.78, 166.70, 136.44, 128.35, 124.91, 121.07, 119.32, 
118.59, 111.43, 109.23, 59.71, 55.60, 31.52, 29.17, 18.76, 16.52. 
 
   
7: Synthesized via general procedure, 21% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.93 (s, 1H), 8.19 – 8.13 (m, 1H), 7.39 (d, J = 7.9 Hz, 
1H), 7.31 (d, J = 8.1 Hz, 1H), 7.04 – 7.00 (m, 1H), 6.98 (d, J = 2.3 Hz, 1H), 6.96 – 6.90 
(m, 1H), 4.05 (q, J = 3.9 Hz, 1H), 3.32 (d, J = 4.7 Hz, 1H), 3.30 – 3.20 (m, 2H), 2.94 (dd, 






















13C NMR (151 MHz, dmso) δ 166.73, 165.53, 136.42, 127.59, 125.46, 121.42, 119.11, 
118.76, 111.68, 108.29, 55.87, 50.84, 33.22, 30.55. 
 
   
 
8: Synthesized via general procedure, 23% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.87 (s, 1H), 8.18 (s, 1H), 7.45 (d, J = 8.0 Hz, 1H), 
7.27 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 8.9 Hz, 2H), 4.10 (d, J = 3.8 Hz, 1H), 3.54 (q, J = 
7.1 Hz, 1H), 3.23 (dd, J = 14.4, 3.8 Hz, 1H), 2.95 (dd, J = 14.5, 4.5 Hz, 1H), 2.47 (d, J = 
2.9 Hz, 1H), 0.18 (d, J = 6.8 Hz, 3H). 
 
13C NMR (151 MHz, dmso) δ 167.51, 165.65, 136.26, 128.11, 125.08, 121.33, 119.33, 
118.76, 111.58, 108.73, 56.73, 56.06, 31.77, 30.56, 17.19. 
 
   
9: Synthesized via general procedure, 43% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.92 – 10.76 (m, 1H), 8.01 (s, 1H), 7.92 (s, 1H), 7.56 
(d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.02 (d, J = 2.2 Hz, 1H), 6.99 (t, J = 7.5 Hz, 
1H), 6.90 (t, J = 7.4 Hz, 1H), 4.09 (s, 1H), 3.51 (s, 1H), 3.21 (dd, J = 14.5, 4.4 Hz, 1H), 
3.00 (dd, J = 14.5, 4.6 Hz, 1H), 1.17 – 1.02 (m, 1H), 0.81 (dp, J = 14.1, 7.2 Hz, 1H), 





















13C NMR (151 MHz, dmso) δ 167.57, 167.21, 136.34, 128.30, 124.95, 121.11, 119.40, 
118.64, 111.43, 109.05, 55.74, 55.33, 29.22, 26.43, 8.46. 
 
  10: Synthesized via general procedure, 32% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.89 (d, J = 2.4 Hz, 1H), 8.08 (s, 1H), 7.75 (d, J = 2.5 
Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.00 (dd, J = 7.3, 5.0 Hz, 2H), 
6.91 (d, J = 7.5 Hz, 1H), 5.00 (ddt, J = 17.1, 10.2, 7.1 Hz, 1H), 4.59 (dd, J = 10.1, 2.3 
Hz, 1H), 4.37 (dd, J = 17.0, 2.2 Hz, 1H), 4.09 (d, J = 2.8 Hz, 1H), 3.68 – 3.51 (m, 1H), 
3.23 (dd, J = 14.4, 4.1 Hz, 1H), 2.97 (dd, J = 14.4, 4.7 Hz, 1H), 1.94 – 1.68 (m, 1H), 
1.17 (dt, J = 14.4, 7.5 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 167.23, 166.73, 136.29, 133.66, 128.28, 125.12, 121.19, 
119.47, 118.76, 118.05, 111.48, 108.89, 55.78, 54.10, 38.55, 29.31. 
 
  11: Synthesized via general procedure, 28% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.86 (d, J = 2.5 Hz, 1H), 8.00 (dd, J = 29.8, 2.2 Hz, 
2H), 7.52 (d, J = 7.9 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.11 (d, J = 2.3 Hz, 1H), 7.02 (t, J 
= 7.5 Hz, 1H), 6.93 (t, J = 7.4 Hz, 1H), 4.10 (s, 1H), 3.83 (s, 1H), 3.24 – 3.05 (m, 2H), 




















13C NMR (151 MHz, dmso) δ 167.51, 165.97, 136.35, 128.07, 124.69, 121.28, 119.11, 
118.80, 111.59, 109.29, 80.70, 73.87, 55.62, 53.54, 30.20, 23.75. 
 
  12: Synthesized via general procedure, 29% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.86 (s, 1H), 8.02 (s, 1H), 7.90 (d, J = 2.3 Hz, 1H), 
7.54 (d, J = 7.9 Hz, 1H), 7.27 (d, J = 8.1 Hz, 1H), 7.02 – 6.97 (m, 2H), 6.89 (t, J = 7.4 
Hz, 1H), 4.08 (q, J = 3.6 Hz, 1H), 3.45 (q, J = 4.5, 3.1 Hz, 1H), 3.23 (dd, J = 14.4, 4.0 
Hz, 1H), 2.97 (dd, J = 14.4, 4.7 Hz, 1H), 2.47 (t, J = 2.0 Hz, 1H), 1.00 – 0.76 (m, 1H), 
0.65 – 0.29 (m, 5H). 
 
13C NMR (151 MHz, dmso) δ 167.41, 167.36, 136.36, 128.31, 125.04, 121.10, 119.44, 
118.69, 111.41, 108.99, 55.84, 54.36, 36.07, 29.28, 17.15, 14.00. 
  
  13: Synthesized via general procedure, 41% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.86 (d, J = 2.3 Hz, 1H), 8.14 (d, J = 2.1 Hz, 1H), 8.06 
(d, J = 2.2 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.22 – 7.13 (m, 3H), 7.07 (t, J = 7.4 Hz, 
1H), 7.03 (d, J = 2.2 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.92 (t, J = 7.4 Hz, 1H), 6.75 (d, J 
= 7.5 Hz, 2H), 4.13 (d, J = 4.5 Hz, 1H), 3.57 (d, J = 5.9 Hz, 1H), 3.40 – 3.22 (m, 2H), 
2.99 (dd, J = 14.4, 4.6 Hz, 1H), 1.78 (ddq, J = 25.4, 13.8, 6.8, 5.2 Hz, 2H), 1.21 (tt, J = 




















13C NMR (151 MHz, dmso) δ 167.46, 167.05, 141.84, 136.26, 128.46, 128.44, 128.32, 
125.92, 125.16, 121.07, 119.48, 118.73, 111.61, 108.87, 55.81, 54.14, 35.47, 29.93, 
29.22. 
 
  14: Synthesized via general procedure, 26% yield over 3 steps. 
 
 
1H NMR (599 MHz, DMSO-d6) δ 10.83 (d, J = 2.4 Hz, 1H), 10.41 (s, 1H), 8.40 (d, J = 
5.9 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.1 Hz, 2H), 7.29 (d, J = 8.0 Hz, 1H), 
7.21 (d, J = 2.3 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.03 – 6.96 
(m, 1H), 3.85 (dt, J = 9.0, 5.6 Hz, 1H), 3.20 (dd, J = 14.9, 5.2 Hz, 1H), 2.97 (dd, J = 
14.9, 9.3 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 171.96, 168.01, 137.21, 136.46, 132.65, 130.80, 127.36, 
126.65, 124.74, 124.31, 121.38, 121.34, 118.75, 118.67, 111.81, 110.05, 23.95. 
 
 
  15: Synthesized via general procedure, 41% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.88 (d, J = 2.4 Hz, 1H), 8.14 (d, J = 2.1 Hz, 1H), 7.96 
(d, J = 2.1 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.02 – 6.96 (m, 
2H), 6.90 (t, J = 7.5 Hz, 1H), 4.11 (d, J = 4.3 Hz, 1H), 3.64 (d, J = 5.8 Hz, 1H), 3.25 (dd, 


















(ddq, J = 28.7, 18.2, 6.0, 5.1 Hz, 2H), 1.18 (ddt, J = 15.5, 10.7, 5.5 Hz, 1H), 1.01 – 0.82 
(m, 1H). 
 
13C NMR (151 MHz, dmso) δ 167.37, 166.77, 136.24, 128.23, 125.08, 121.09, 119.45, 
118.72, 111.66, 108.82, 55.78, 53.42, 33.13, 29.20, 28.04, 14.67. 
 
  16: Synthesized via general procedure, 45% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.88 (d, J = 2.3 Hz, 1H), 8.01 (d, J = 2.5 Hz, 1H), 7.94 
(d, J = 2.7 Hz, 1H), 7.92 (s, 0H), 7.52 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.04 
– 6.96 (m, 2H), 6.89 (t, J = 7.5 Hz, 1H), 4.05 (d, J = 3.4 Hz, 1H), 3.40 (dt, J = 9.5, 3.6 
Hz, 1H), 3.22 (dd, J = 14.4, 4.0 Hz, 1H), 2.95 (dd, J = 14.4, 4.7 Hz, 1H), 1.59 – 1.30 (m, 
4H), 1.10 – 0.87 (m, 5H), 0.67 (ddd, J = 13.7, 9.2, 4.5 Hz, 1H), 0.39 (q, J = 11.0, 10.4 
Hz, 2H), -0.11 (ddd, J = 14.0, 9.6, 4.8 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 168.03, 167.55, 162.72, 136.33, 128.19, 125.02, 121.10, 
119.42, 118.73, 111.55, 108.93, 55.96, 52.00, 42.55, 36.21, 33.28, 32.32, 31.68, 31.20, 
31.13, 29.58, 26.42, 26.09, 25.73. 
 
  17: Synthesized via general procedure, 21% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.86 (s, 1H), 8.36 (d, J = 7.5 Hz, 1H), 7.73 (s, 1H), 
7.46 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.13 (d, J = 2.2 Hz, 1H), 7.08 – 7.01 




















1H), 3.57 (d, J = 1.2 Hz, 3H), 3.15 (dd, J = 14.7, 5.6 Hz, 1H), 3.05 (dd, J = 14.6, 8.5 Hz, 
1H), 2.31 – 2.14 (m, 1H), 2.03 (qdd, J = 16.2, 9.8, 6.6 Hz, 2H), 1.76 (ddt, J = 13.5, 9.3, 
4.6 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 177.84, 173.15, 172.62, 136.52, 127.41, 124.24, 121.42, 
118.88, 118.37, 111.88, 109.70, 55.61, 53.46, 52.35, 29.45, 27.33, 25.59. 
 
 
  18: Synthesized via general procedure, 53% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.89 (d, J = 2.4 Hz, 1H), 8.03 (d, J = 2.6 Hz, 1H), 7.93 
(d, J = 2.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.27 (d, J = 8.1 Hz, 1H), 7.04 – 6.96 (m, 
2H), 6.89 (t, J = 7.4 Hz, 1H), 4.06 (d, J = 3.4 Hz, 1H), 3.36 (dt, J = 8.1, 3.6 Hz, 1H), 3.23 
(dd, J = 14.4, 4.0 Hz, 1H), 2.95 (dd, J = 14.4, 4.7 Hz, 1H), 1.22 – 1.08 (m, 1H), 0.60 
(ddd, J = 13.6, 9.2, 4.6 Hz, 1H), 0.49 (d, J = 6.5 Hz, 3H), 0.39 (d, J = 6.6 Hz, 3H), -0.06 
(ddd, J = 14.0, 9.4, 5.1 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 167.88, 167.51, 136.33, 128.21, 125.06, 121.18, 119.42, 
118.76, 111.52, 108.92, 55.96, 52.77, 44.11, 29.54, 23.28, 23.12, 21.69. 
 
  19: Synthesized via general procedure, 42% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.84 – 10.69 (m, 1H), 8.40 (d, J = 2.4 Hz, 0H), 7.51 – 






















6.92 – 6.87 (m, 1H), 6.81 – 6.71 (m, 1H), 5.24 (d, J = 16.5 Hz, 1H), 4.02 (d, J = 16.5 Hz, 
1H), 3.92 (dd, J = 11.8, 4.1 Hz, 1H), 3.25 (dd, J = 14.4, 4.0 Hz, 1H), 3.05 (dd, J = 14.4, 
4.5 Hz, 1H), 2.57 (dd, J = 14.6, 4.1 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 166.13, 165.10, 136.25, 136.15, 129.59, 128.15, 126.67, 
124.49, 121.15, 121.12, 119.01, 118.88, 118.64, 117.79, 111.36, 111.33, 108.46, 
105.90, 56.27, 55.83, 30.64, 26.10. 
 
 
  20: Synthesized via general procedure, 46% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.88 (d, J = 2.4 Hz, 1H), 9.14 (s, 1H), 7.81 (d, J = 2.6 
Hz, 1H), 7.62 (d, J = 2.7 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.12 
– 7.02 (m, 1H), 7.01 – 6.93 (m, 2H), 6.56 (d, J = 8.0 Hz, 2H), 6.49 (d, J = 8.0 Hz, 2H), 
4.29 (d, J = 4.5 Hz, 1H), 3.98 – 3.82 (m, 1H), 3.79 – 3.66 (m, 1H), 3.46 (p, J = 5.9 Hz, 
1H), 2.76 (dd, J = 14.5, 4.3 Hz, 1H), 2.45 – 2.25 (m, 2H), 1.76 (dd, J = 13.6, 7.0 Hz, 
1H), 1.42 – 1.21 (m, 2H), 0.99 (dd, J = 6.2, 1.1 Hz, 3H), 0.80 (td, J = 7.4, 1.1 Hz, 3H). 
 
13C NMR (151 MHz, dmso) δ 167.16, 166.66, 156.39, 136.48, 131.13, 127.89, 126.82, 
124.79, 121.29, 119.15, 118.83, 115.30, 111.74, 109.31, 67.57, 56.30, 55.65, 32.14, 
30.39, 23.53, 10.54. 
 




















1H NMR (599 MHz, DMSO-d6) δ 10.87 (d, J = 2.5 Hz, 1H), 7.90 (d, J = 2.5 Hz, 1H), 7.70 
(d, J = 2.7 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.22 – 7.10 (m, 
3H), 7.04 (t, J = 7.5 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 6.69 – 
6.65 (m, 2H), 3.94 (s, 1H), 3.82 (t, J = 4.1 Hz, 1H), 2.77 (dd, J = 14.5, 4.4 Hz, 1H), 2.46 
(ddd, J = 39.5, 13.9, 5.3 Hz, 2H), 1.82 (dd, J = 13.5, 7.1 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 167.22, 166.59, 136.94, 136.45, 130.13, 128.46, 127.94, 
126.79, 124.84, 121.31, 119.19, 118.84, 111.76, 109.21, 56.04, 55.68, 30.12. 
 
22: Synthesized via general procedure, 55% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.82 (d, J = 2.5 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.82 
(d, J = 2.1 Hz, 1H), 7.57 (d, J = 7.9 Hz, 1H), 7.26 (s, 0H), 7.02 (d, J = 2.2 Hz, 1H), 6.98 
(dd, J = 8.1, 6.8 Hz, 1H), 6.89 (t, J = 7.4 Hz, 1H), 3.50 – 3.47 (m, 1H), 3.21 (dd, J = 
14.5, 4.5 Hz, 1H), 3.01 (dd, J = 14.4, 4.6 Hz, 1H), 1.27 (ddt, J = 10.4, 7.3, 3.6 Hz, 1H), 
0.63 – 0.21 (m, 8H). 
 
13C NMR (151 MHz, dmso) δ 167.59, 166.65, 136.40, 128.42, 125.02, 121.03, 119.41, 
118.60, 111.37, 109.19, 59.30, 55.60, 38.30, 28.87, 23.27, 14.87, 12.06. 
 
   























1H NMR (599 MHz, DMSO-d6) δ 10.82 (d, J = 2.4 Hz, 1H), 7.69 (d, J = 2.6 Hz, 1H), 7.32 
(d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.01 (t, J = 7.5 Hz, 1H), 6.92 (t, J = 7.4 Hz, 
1H), 6.56 (d, J = 2.3 Hz, 1H), 3.88 – 3.79 (m, 1H), 3.32 (s, 1H), 2.67 (dd, J = 14.3, 4.2 
Hz, 1H), 2.14 (dd, J = 14.3, 6.7 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 167.14, 136.46, 127.76, 124.83, 121.21, 118.96, 118.77, 
111.68, 109.17, 55.69, 30.42. 
 
  24: Synthesized via general procedure, 41% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.89 (dd, J = 8.0, 2.3 Hz, 1H), 9.05 (s, 1H), 8.70 (dd, 
J = 123.2, 7.5 Hz, 1H), 7.44 (t, J = 8.2 Hz, 2H), 7.32 (t, J = 7.6 Hz, 1H), 7.21 (t, J = 8.3 
Hz, 1H), 7.19 – 7.12 (m, 2H), 7.04 (dd, J = 9.3, 5.8 Hz, 1H), 6.99 (t, J = 7.5 Hz, 1H), 
6.95 (t, J = 7.4 Hz, 1H), 4.95 (dd, J = 11.0, 4.0 Hz, 1H), 4.51 – 4.41 (m, 1H), 3.44 (dd, J 
= 16.8, 11.0 Hz, 1H), 3.21 – 3.01 (m, 3H), 2.93 (dd, J = 16.8, 4.0 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 172.56, 172.49, 170.59, 161.10, 158.87, 141.92, 136.45, 
130.31, 127.90, 127.48, 126.05, 125.26, 124.25, 124.12, 124.05, 121.38, 118.84, 
118.43, 118.35, 111.83, 110.13, 109.46, 58.02, 53.79, 53.58, 52.42, 52.30, 33.04, 
27.29. 
 



















1H NMR (599 MHz, DMSO-d6) δ 10.89 (d, J = 2.4 Hz, 1H), 8.27 (dd, J = 22.8, 2.3 Hz, 
2H), 7.54 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.11 – 7.06 (m, 1H), 7.06 – 6.98 
(m, 2H), 6.94 (t, J = 7.5 Hz, 2H), 6.89 (t, J = 7.4 Hz, 1H), 6.35 (d, J = 7.6 Hz, 2H), 4.73 
(d, J = 2.1 Hz, 1H), 4.22 (dd, J = 4.5, 2.4 Hz, 1H), 3.28 (dd, J = 14.3, 4.3 Hz, 1H), 3.01 
(dd, J = 14.3, 4.6 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 166.70, 165.51, 139.44, 136.42, 128.34, 128.06, 127.63, 
127.57, 125.19, 121.22, 119.48, 118.83, 111.52, 108.92, 58.86, 55.92, 29.13. 
 
  27: Synthesized via general procedure, 27% yield over 3 steps. 
 
1H NMR (599 MHz, dmso) δ 10.90, 10.89, 8.13, 8.13, 7.46, 7.45, 7.27, 7.26, 7.01, 7.00, 
7.00, 6.99, 6.99, 6.92, 6.91, 6.91, 6.89, 4.11, 4.10, 4.10, 4.09, 3.43, 3.42, 3.41, 3.41, 
3.24, 3.23, 3.21, 3.21, 2.97, 2.96, 2.95, 2.94, 2.59. 
 
13C NMR (151 MHz, dmso) δ 167.19, 166.15, 136.46, 128.24, 124.94, 121.25, 119.27, 
118.72, 111.65, 108.99, 59.36, 56.32, 41.57, 32.49, 30.30, 24.80, 23.06, 21.74. 
 
  28: Synthesized via general procedure, 25% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.89 (d, J = 2.4 Hz, 1H), 7.97 (d, J = 3.0 Hz, 1H), 7.40 
(d, J = 7.9 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.20 (t, J = 7.4 Hz, 2H), 7.15 (t, J = 6.9 Hz, 
1H), 7.08 – 7.02 (m, 1H), 6.96 (t, J = 7.4 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 6.78 – 6.74 






















Hz, 1H), 2.61 (s, 3H), 2.51 (dd, J = 14.0, 5.0 Hz, 1H), 2.10 (t, J = 6.4 Hz, 1H), 2.07 (t, J 
= 6.0 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 166.13, 166.04, 137.44, 136.57, 129.96, 128.72, 127.77, 
127.07, 124.77, 121.35, 118.96, 118.83, 111.84, 109.39, 63.17, 55.88, 38.15, 33.23, 
30.98. 
 
  29: Synthesized via general procedure, 24% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.86 (d, J = 2.5 Hz, 1H), 7.94 (d, J = 12.4 Hz, 2H), 
7.56 (d, J = 7.9 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 6.99 (t, J = 
7.5 Hz, 1H), 6.90 (t, J = 7.4 Hz, 1H), 4.12 (td, J = 4.2, 1.8 Hz, 1H), 3.24 (dd, J = 14.4, 
3.9 Hz, 1H), 2.98 (dd, J = 14.4, 4.6 Hz, 1H), 1.11 (s, 3H), 0.39 (s, 3H). 
 
13C NMR (151 MHz, dmso) δ 170.61, 166.65, 136.17, 128.24, 125.00, 121.18, 119.48, 
118.76, 111.48, 108.90, 56.12, 55.12, 29.27, 28.73, 27.98. 
 
  30: Synthesized via general procedure, 30% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.90 (d, J = 2.4 Hz, 1H), 8.08 (d, J = 2.7 Hz, 1H), 7.75 
(d, J = 2.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.04 – 7.00 (m, 
2H), 6.92 (t, J = 7.4 Hz, 1H), 3.99 (q, J = 4.1 Hz, 1H), 3.28 (dd, J = 17.3, 3.0 Hz, 1H), 




















13C NMR (151 MHz, dmso) δ 168.38, 166.12, 136.36, 127.91, 125.03, 121.33, 119.13, 
118.87, 111.61, 108.78, 55.88, 44.28, 29.61. 
 
  31: Synthesized via general procedure, 34% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.84 (d, J = 2.4 Hz, 1H), 8.02 (d, J = 3.0 Hz, 1H), 7.77 
(d, J = 3.0 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.12 (d, J = 2.3 
Hz, 1H), 7.10 – 6.98 (m, 1H), 6.93 (t, J = 7.4 Hz, 1H), 4.97 (d, J = 5.9 Hz, 1H), 4.29 (dd, 
J = 4.6, 0.8 Hz, 1H), 3.89 (td, J = 7.6, 6.4, 3.2 Hz, 1H), 3.74 (pd, J = 6.4, 2.9 Hz, 1H), 
3.49 (t, J = 3.1 Hz, 1H), 3.48 – 3.44 (m, 1H), 3.24 – 3.16 (m, 2H), 1.29 (dddd, J = 16.2, 
13.3, 10.5, 6.4 Hz, 2H), 0.99 (d, J = 6.1 Hz, 2H), 0.92 (d, J = 6.5 Hz, 3H), 0.80 (t, J = 7.4 
Hz, 2H). 
 
13C NMR (151 MHz, dmso) δ 168.32, 166.89, 136.58, 128.06, 124.42, 121.20, 118.96, 
118.69, 111.65, 110.13, 67.61, 67.57, 60.82, 56.20, 32.14, 31.62, 23.53, 20.11, 10.54. 
 
  32: Synthesized via general procedure, 22% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.91 (d, J = 2.5 Hz, 1H), 8.20 (d, J = 2.4 Hz, 1H), 8.16 
(d, J = 2.3 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.02 (t, J = 7.5 Hz, 
1H), 7.00 (d, J = 2.2 Hz, 1H), 6.89 (t, J = 7.5 Hz, 1H), 6.37 – 6.31 (m, 2H), 6.17 – 6.11 
(m, 2H), 4.59 (t, J = 1.8 Hz, 1H), 4.17 (dd, J = 4.4, 2.3 Hz, 1H), 3.25 (dd, J = 14.3, 4.5 





















13C NMR (151 MHz, dmso) δ 166.60, 165.99, 156.92, 136.39, 129.84, 128.72, 128.34, 
125.16, 121.19, 119.47, 118.80, 114.84, 111.48, 108.97, 58.40, 55.92, 29.12. 
 
  33: Synthesized via general procedure, 17% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.87 (d, J = 2.6 Hz, 1H), 7.92 (d, J = 2.1 Hz, 1H), 7.64 
(d, J = 2.1 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.09 (d, J = 2.3 
Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.93 (t, J = 7.4 Hz, 1H), 6.88 (d, J = 8.2 Hz, 2H), 4.14 – 
4.07 (m, 1H), 3.97 (ddd, J = 9.9, 4.5, 1.8 Hz, 1H), 3.18 (dd, J = 14.6, 5.5 Hz, 1H), 3.07 
(dd, J = 14.6, 4.5 Hz, 1H), 2.14 (dd, J = 15.6, 4.4 Hz, 1H), 1.45 (dd, J = 15.6, 8.3 Hz, 
1H). 
 
13C NMR (151 MHz, dmso) δ 171.84, 167.65, 167.34, 136.31, 128.08, 124.84, 121.31, 
119.24, 118.83, 111.68, 109.28, 55.62, 51.71, 38.63, 29.10. 
 
  34: Synthesized via general procedure, 44% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.89 (d, J = 2.5 Hz, 1H), 8.02 (d, J = 2.8 Hz, 1H), 7.89 
(s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.08 – 6.97 (m, 2H), 6.92 (t, J 
= 7.4 Hz, 1H), 4.01 (q, J = 4.2 Hz, 1H), 3.22 (dd, J = 14.4, 4.7 Hz, 1H), 2.98 (dd, J = 























13C NMR (151 MHz, dmso) δ 168.90, 168.56, 136.33, 127.93, 124.96, 121.32, 119.15, 
118.87, 111.60, 108.83, 56.36, 49.19, 29.58, 18.78. 
 
 37: Synthesized via general procedure, 25% yield over 3 steps. 
 
1H NMR (599 MHz, DMSO-d6) δ 10.90 (s, 1H), 8.17 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 
7.27 (d, J = 8.1 Hz, 1H), 6.99 (t, J = 7.6 Hz, 1H), 6.95 (s, 1H), 6.90 (t, J = 7.5 Hz, 1H), 
4.18 (d, J = 12.8 Hz, 1H), 4.11 (s, 1H), 3.45 – 3.25 (m, 4H), 2.89 (d, J = 4.6 Hz, 0H), 
2.14 (t, J = 12.8 Hz, 1H), 1.34 (d, J = 12.7 Hz, 1H), 1.17 – 0.96 (m, 3H), 0.08 (dd, J = 
18.1, 8.8 Hz, 1H), -0.82 (tt, J = 12.8, 6.0 Hz, 1H). 
 
13C NMR (151 MHz, dmso) δ 166.51, 163.69, 136.16, 128.23, 125.38, 121.30, 119.53, 











NMR Data for Heterodimer 37 
  
1H NMR (599 MHz, Methanol-d4) δ 8.50 (s, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.51 – 7.49 
(m, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.19 (s, 0H), 7.16 (s, 1H), 7.12 (dt, J = 14.7, 7.1 Hz, 
1H), 7.06 (t, J = 7.7 Hz, 1H), 7.02 (s, 0H), 7.01 – 6.95 (m, 1H), 6.87 (d, J = 7.5 Hz, 1H), 
5.83 (s, 0H), 4.43 – 4.27 (m, 1H), 3.91 (dd, J = 11.1, 6.3 Hz, 1H), 3.66 (d, J = 5.2 Hz, 
1H), 3.54 – 3.40 (m, 1H), 3.39 – 3.30 (m, 0H), 3.25 – 3.12 (m, 1H), 3.09 (dd, J = 14.6, 
4.2 Hz, 1H), 2.95 (t, J = 12.0 Hz, 1H), 2.81 (dd, J = 12.0, 5.5 Hz, 1H), 2.54 (dd, J = 12.0, 
5.5 Hz, 1H), 1.83 (dt, J = 12.9, 6.8 Hz, 1H), 1.59 (p, J = 10.5, 10.0 Hz, 1H), 1.43 – 1.26 
(m, 2H), 1.12 (t, J = 4.8 Hz, 2H), 0.76 – 0.58 (m, 1H). 
 
 
13C NMR (151 MHz, cd3od) δ 168.98, 166.28, 165.74, 149.25, 135.36, 129.96, 129.25, 
125.58, 125.25, 124.48, 123.47, 121.65, 121.51, 119.25, 119.07, 118.90, 118.83, 
117.96, 111.34, 110.98, 109.86, 108.49, 107.09, 77.42, 72.48, 70.07, 58.55, 57.62, 














































































































































































































































































































































































































































































Preliminary Studies in the Structure and Mechanism of Bacterial 
Diketopiperazine Dimer Forming Cytochrome P450, NascB-F5053  
 
4.1 Abstract 
Chapters 2 and 3 described the initial discovery and characterization of the (+)- 
and (–)-naseseazines gene clusters, the pected discovery of the (–)-aspergilazine 
biosynthetic gene cluster, subsequent characterization of the encoded cytochromes 
P450. However, as stated at the outset of this dissertation, our original goal was not 
only the discovery these clusters, but to decipher the underlying molecular mechanisms 
behind the selectivity displayed by the enzymes that catalyze oxidative C–C and C–N 
bond formation. To that end, we report the structure of NascB-F5053, the cytochrome 
P450 which forms both the (–)-naseseazine and (–)-aspergilazine scaffold. To that end 
we obtained a 1.5 Å structure of NascB-F5053 in complex with two units of the native 
substrate 3 bound in the active site. Preliminary mutational analysis of the active site 
identified key residues requisite for binding, catalysis and selectivity. Further analysis of 
possible reaction mechanisms was also interrogated using synthetic probes and 
computational chemistry. All experimental structural work in this Chapter was performed 
by Dr. Sean Newmister, and computational work by Dr. Jacob Sanders (UCLA). 
 
 
Figure 4-1. Native reaction of NascB-F5053. 
 


















































Dimeric diketopiperazine natural products are a large family of natural products 
with over 100 members isolated to date. Notably, the biological activity of these natural 
products is tethered not necessarily to their amino acid composition, but rather the 
regiochemistry and stereochemistry of dimerization. (+)-WIN 64821 (4) and (–)-
ditryptophenaline (5) are of identical amino acid composition, however the configuration 
of the 4 contiguous stereocenters in 4 (C2,C2’,C3, and C3’) are all R, while the 
corresponding carbons in 5 are all S1. Despite their near identical composition, 4 is a 




Figure 4-2. Structures of WIN 64821 (4) and (–)-ditryptophenaline (5). 
 
While great efforts have been made in development of synthetic methods to 
access these complex molecules, the functionality of key intermediates in these 
syntheses installed to direct bond formation limit the potential product to a single regio- 
and stereochemical outcome. Our own studies as well as literature precedent3, 7 has 
shown that the biosynthetic machinery that catalyzes dimerization is innately flexible, 
and capable of accommodating a variety of monomeric building blocks into dimers. In a 
directed biosynthesis study of the (+)-WIN 64821 producing Aspergillus sp. SC319, 
feeding a variety of amino acid starting materials resulted in the production of 36 
analogues of 4 with substitution on the indoline ring (from functionalized tryptophans), 
substitution on the phenyl ring (functionalized phenylalanine), and complete substitution 
of phenylalanine for aliphatic amino acids. While this strategy enabled the rapid and 
facile assembly of complex congeners for structure activity relationships (SAR), this 
technique again only allows for a single regio- and stereochemical outcome, and is 


































Figure 4-3. Directed biosynthesis of (+)-WIN 64821 analogues. 
 
To access alternative configurations and connectivities, we hope to achieve a 
fundamental understanding of the molecular underpinning behind the exquisite 
selectivity displayed by these dimerization enzymes. As reported in Chapters 2 and 3, 
we have recently discovered cytochromes P450 from bacterial biosynthetic pathways 
involved in the biosynthesis of the (+)-naseseazine, (–)-naseseazine, and (–)-
aspergilazine diketopiperazine dimers. These enzymes offer us a unique opportunity to 
study their dimerization selectivity, as they each display their own unique 
stereochemical and site-selectivity. To this end, we sought to crystallize these enzymes 
in complex with their substrate and/or product and interrogate the residues surrounding 
the active site to uncover how they may affect the reaction selectivity, as well as 
uncover the possible mechanism for this oxidative dimerization. 
 
4.3 Results and Discussion 
In selecting candidate enzymes for crystallization, we chose to exclude NznB as 
it was typically obtained in low yields from protein purification (3-4 mg/L), and was the 
least stable as indicated by its low turnover number and precipitation during purification 
and in vitro reactions. Of the remaining cytochromes, NascB-F5053 was selected as it 
consistently had the highest turnover numbers in biocatalytic reactions, and was 
capable of producing both (–)-naseseazine C (1) and (–)-aspergilazine (2), and 
crystallography offered a route to understand this enzyme’s ability to catalyze two 
different bond forming cascades. Ultimately, we were able to obtain a 1.5 Å crystal 
structure (Figure 4-4, left) of NascB-F5053 in complex with two units of substrate 3 
























fold, and the cytochrome P450 to which it bears the most structural similarity (2.3 Å 
rmsd, DALI21)8 is another carbon–carbon bond forming cytochrome, CYP121 from 
Mycobacterium tuberculosis (PDB 4G1X). Unlike CYP121, and other structurally 
characterized C–C bond forming cytochromes P450,9-12 both substrates are buried side-
by-side, deep in the active site directly above the plane of the heme cofactor.  
 
Figure 4-4. Left: Full view of crystal structure NascB-F5053wt.  
Right: Close up of active site showing unambiguous electron density of substrates shown in blue mesh (F0-Fs) with 




Figure 4-5. Active site of NascB-F5053wt showing two units of 3 bound in the active site and residues within 5 Å of 
either substrate. 
 
4.3.1 Donor and Acceptor Substrate Binding Pockets 
 Given the high selectivity displayed in the assembly of non-symmetrical 
diketopiperazine dimers by NascB-F5053, in the previous chapter we hypothesized that 
within the active site there must be two dissimilar substrate binding sites in order to 
position the northern monomer, (referred to as the donor, colored blue in Figure 6) and 





Figure 4-6. Donor and acceptor nomenclature. 
 
4.3.2 Donor binding site 
In Chapter 3 we described the heterodimerization reaction of 3 and 6, wherein a 
single heterodimer, 7 was formed (Figure 4-6) and from this we gleaned that the 
acceptor pocket possesses a more relaxed substrate specificity, as it is able to 
accommodate the bulkier tryptophan side chain, while the donor pocket is more 
selective for its substrate and unable to accommodate larger DKP monomers. 
Examination of the donor-binding site (residues within 5 Å of the donor monomer) 
support this hypothesis, as the donor is completely enveloped by active site residues, 
with Phe390, Phe391,Gln75 and Glu76 completely surrounding the proline side chain 
leaving no space for larger amino acid side chains. Ser287 and Lys292 are hydrogen 
bonding with the carbonyl oxygens of the diketopiperazine, with Lys292 also hydrogen 





































































Figure 4-7. Donor binding pocket with residues within 5 Å of donor monomer colored as green sticks and labeled. 
 
4.3.3 Acceptor binding site 
Within 5 Å of the acceptor DKP there are only 3 amino acid residues (Figure 4-8). 
Lys292 is hydrogen bonding to carbonyl oxygens on both the donor and acceptor DKP, 
acting as a bridging residue between both binding sites. Gln68 lies directly behind the 
diketopiperazine core, while Phe 391 making edge-to-edge contact with the tryptophan 
arm of acceptor diketopiperazine. The lack of residues making van der Waals 
interactions with the acceptor residue may explain its substrate flexibility, as there are 
no residues around the proline side chain of the acceptor leaving space for larger 




Figure 4-8. Acceptor binding pocket with residues within 5Å of acceptor monomer. 
 
4.3.4. Structure Informed Mechanism 
The substrates in the active site adopt a conformation such that the N–H of the 
indole the acceptor DKP (Figure 4-9, teal), and the C5–H of the donor DKP (Figure 9, 
yellow) both directed toward the axial water ligand. Based on this complex and literature 
precedent for bacterial C–C bond forming P450s,9-12 we propose the following 
mechanism for dimerization (Figure 4-10). We hypothesize the initial substrate radical is 
generated from Michaelis complex A (Figure 10) via proton-coupled electron transfer 
(PCET), either through direct interaction with the heme or assisted by hydrogen bonding 
to yield intermediate B (Figure 10). A series of proton transfer steps yields cyclization of 
the pyrroloindoline to intermediate C (Figure 10). Carbon-carbon bond formation and 
dearomatization of donor yields intermediate D (Figure 10), which rearomatizes via 





Figure 4-9. Active site showing bond to be formed and bonds (hypothetically) broken during dimerization reaction.  
 
 
Figure 4-10. Proposed reaction mechanism based on structure. 
 
4.3.5 Molecular Dynamics Simulations  
Despite the regiochemistry for (–)-naseseazine being represented in the 
conformation of both substrates in the active site, and both reactive hydrogen atoms 
being oriented for catalysis, if the conformation of the substrates found in the crystal 
structure were to remain static throughout the course of the reaction, the stereochemical 
configuration of the product would not reflect that found experimentally in the product (–










































































































      
Figure 4-11. Left: conformation of substrates in active site, Right: 3D model of (–)-naseseazine C (1). 
 
To evaluate how the protein, and specifically active site might undergo 
remodeling during the course of catalysis we worked with our collaborators in the Houk 
lab to model how the substrates may move during the course of a Molecular Dynamics 
(MD) simulation. The heme cofactor was modeled as both the resting state and and 
iron-oxo (compound 1) oxidations states, however under neither condition did 
conformation of the acceptor change dramatically enough to allow for formation of the 
desired stereochemistry. However, when the iron center was modeled as the compound 
1 iron-oxo species, within the first 100 nanoseconds of the simulation, the indole N–H 
moved away from the iron-oxo and the N–H of the diketopiperazine moved within 2-4 Å 





Figure 4-12. Top left: Snapshot of MD simulation at initial conformation, Top right, Snapshot of MD simulation at 300 
microseconds. Bottom: Graphical representation of bond distances throughout MD simulation. 
 
Based on this simulation we postulated that there may be a second possible 
mechanism where the cyclization-dimerization cascade is initiated by H–atom 
abstraction from the amide N–H from the diketopiperazine core rather than the N–H of 

















Figure 4-13. Alternative reaction mechanism based on MD simulations. 
 
4.3.6 First Generation Mechanistic Probes 
To evaluate the possibility for DKP N-H abstraction a probe molecule was 
synthesized wherein the indole N–H was “protected” as a simple methyl group. When 
subjected to standard reaction conditions, no dimer was observed however a single 
product was formed exclusively whose mass represented a hydroxylated product 


















































































































Figure 4-14. HPLC trace from reaction of first generation mechanistic probe, 8, with NascB-F5053. 
 
We hypothesized this product may be generated via two different paths, either 
hydroxylation via radical rebound of a radical intermediate, or alternatively via hydration 
of an intermediate carbocation generated from single electron oxidation of key radical 
intermediate (Figure 4-15). 
 
 













































































–OH derived from O2





















Close examination of the active site revealed a residue outside of 5 Å, Glu317, 
which forms an ordered hydrogen-bonding network with the indole N–H of the donor 
diketopiperazine. Using PROPKA,13 E317 was shown to be 100% buried with a 




Figure 4-16. Crystal structure highlighting E317 interaction with donor monomer 3. 
 
Given this interaction, we hypothesized that E317 may be requisite for catalysis. 
If charged, E317A and the ordered waters may be partially deprotonating the indole N–
H of the donor DKP, increasing the electron density of this monomer, activating the 
indole as a nucleophile in a Friedel-Crafts-type mechanism (Figure 4-17). To determine 
the role E317 may play in the reaction mechanism the E317A variant was generated 




Figure 4-17. E317 may be partially deprotonating indole N–H from donor monomer, increasing electron density of 
indole and activating it for nucleophilic attack. 
 
The E317A variant is still catalytically competent for both the native 
homodimerization reaction as well as generating the hydroxylated shunt from 
mechanistic probe 8 (Figure 18). While E317 may not play a direct role in catalysis, we 
sought to design a set of two, second-generation probes for heterodimerization. Probing 
the reaction mechanism for an unsymmetrical dimerization using two units of the same 
substrate (homodimerization) does not allow steric or electronic differentiation of the 
electrophile and/or the nucleophile as the same molecule plays both roles. In a selective 
heterodimerization, where one monomer always assumes the role of nucleophile and 
the other electrophile, the option to differentiate these substrates emerges and enables 
studying the reaction mechanism through traditional techniques for radical substitution 













































Figure 4-18. HPLC trace showing reaction with wt v.s. E317A with native substrate 3 and probe molecule 8. 
 
4.3.7 Second Generation Mechanistic Probes 
In the reaction of 3 with 6 with NascB-F5053, a single heterodimeric product is 

















R = H, 3





Figure 4-19. HPLC trace of heterodimerization of 3 and 6 exclusively forming a single product, 10.  
 
We hypothesized that we could use derivatives of these two monomers to 
evaluate the reaction mechanism. Based on the structure, we hypothesized that Q75 
and E76 would preclude 6 from binding in the donor pocket, and would therefore occupy 
the acceptor pocket. To validate this hypothesis and ensure that each substrate can 
only occupy a single binding pocket without interchange, we crystallized NascB-F5053 
with equivalent quantities of 3 and 6 and found that 3 seems to exclusively occupy the 












































Figure 4-20. Active site of NascB-F5053 crystallized in complex with 3 (green) and 6 (yellow) with electron density 
(F0-Fs) shown in blue mesh.  
 
 With this new crystal structure validating our binding hypothesis, we constructed 
second generation probe 9, which based on the NascB heterocomplex of 3 and 6, 
should exclusively occupy the acceptor site and should not be influenced by other donor 
residues such as E317. When subjected to unoptimized reaction conditions with an 
equimolar quantity of 3 to occupy the donor site, no dimer was observed and again a 
hydroxylated shunt product was observed albeit in low conversion. This result 
represents a proof of concept in the ability to separately interrogate the donor and 
acceptor pockets with second generation probes, and further functionalized probes are 
currently being developed concomitant with mutagenic approaches to deciphering the 






Figure 4-21. HPLC trace for reaction of second-generation probe (9) and 3 generates hydroxylated product. 
 
4.3.8. Mutagenesis of Active Site Residues 
 To gain further insight into residues that may play a role in binding, catalytic 
activity, and substrate and product selectivity, alanine scanning mutagenesis of NascB-
F5053 active site residues within 5Å of either substrate was performed (Figure 4-5). 
Thr244 was also selected for mutagenesis as this is the conserved proton donor residue 
required for proton transfer and generation of compound I.15 NascB-F5053 variants 
Q68A, Q75A, and K292A could not be isolated, as when expressed under standard 




























Figure 4-22. SDS-PAGE gel of purified fractions from NascB-F5053 variants, L to R: SeeBlue2 Ladder, NascB-
F5053E76A, NascB-F5053Q75AE76A, NascB-F5053T244A, NascB-F5053S287A, NascB-F5053E317A, NascB-F5053F390A, 
NascB-F5053F391A, NascB-F5053F90AF391A, SeeBlue2 Ladder (total protein concentrations all normalized 10 ug/well). 
 
All soluble variants were subjected to standard reaction conditions with native 
substrate 3 (Figure 4-22). All variants harboring single residue mutations were still 
capable of producing both (–)-naseseazine C (1), as well as (–)-aspergilazine (2) (not 
easily visible in HPLC, but detectable in by MS) albeit in lower yields (Figure 22). 
However, the variant containing both F390A and F391A mutations, completely lost any 
dimerization capacity, and binding of 3 to the active site was no longer detectable by 
UV-Vis spectroscopy. Notably, the T244A variant did not lose its enzymatic activity, a 
rare trait in cytochromes P450, and may suggest that the substrate may donate a proton 
in the generation of compound I, as seen in EryF,15 or NascB-F5053 may have a 





Figure 4-23. HPLC traces of native substrate 3 with NascB-F5053wt and soluble active site variants. 
 
 As previously noted NascB-F5053 is able to catalyze heterodimerizations of large 
substrates such as 6 with native substrate 3, while NascB-CMB-MQ030 cannot perform 
this reaction, or does so in very low conversions (Figure 4-23). Sequence alignment of 
these two enzymes reveals that between the two enzymes only a single active site 


















Figure 4-24. HPLC traces of reaction of 3 and 6 with Nasc-CMB-MQ030, NascB-F5053, and NascB-S1868. 
 
 To determine if Ser287 or another residue contribute to the expanded reactivity 
of NascB-F5053, our panel of variants were assayed for their ability to catalyze the 
heterodimerization of 3 and 6 (Figure 4-25). In contrast to the native reaction, all 
variants with the exception of NascB-F5053Q75AE76A saw a dramatic decrease in 













































Figure 4-25. HPLC traces of reaction of 3 and 6 with NascB-F5053wt and soluble active site variants. 
 
 All reactions were futher analyzed by mass spectrometry, and the NascB-
F5053E317A variant generated a second product whose mass indicated a heterodimeric 
product. This reaction was performed with a higher loading of biocatalyst and the 
generation of this new product was validated by mass spectrometry. NascB-F5053E317A 
can be expressed and purified at relatively high titer (5-8mg/L) and as such the reaction 
was scaled up in vitro (10 mg of 3 and 10 mg of 6) and this product was purified by 
prep-HPLC to yield 3 mg, and the structure of this compound is being validated through 


























Figure 4-26. HPLC trace of reactions of 3 and 6 with NascB-F5053wt and NascB-F5053E317A. 
 
4.4 Discussion 
 The structure of NascB-F5053 was solved as a complex with two units of its 
native substrate 3. Based on this structure we proposed a general mechanism for the 
dimerization of 3, which we probed through synthesis of small molecule probes, 
computational simulations, and mutagenesis. Mutagenesis of active site residues within 
5 Å of either substrate did not alter the reactivity profile with regard to the 
stereochemical or regiochemical outcome of the reaction, however a residue 
hypothesized to be requisite for catalysis Glu317 was exchanged for Ala, a new product 
was formed in the heterodimerization reaction of 3 and 6. Work is currently ongoing in 
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Supplementary Table 4-1. Mutagenic primers used to generate NascB-F5053 
variants 
























General procedures for overexpression, purification and spectral characterization 
of cytochrome P450s  
The expression of pET28b-NznB+09 was performed by transforming the plasmid 
into the competent cell E. coli strain C41 (DE3) and selected on Luria-Bertani (LB) 
medium plates containing100 µg/mL kanamycin. A single colony was grown overnight in 
	 167	
LB broth containing the same concentration of the antibiotics. The main culture was 
prepared by inoculating 1% of each overnight culture into a 2 L baffled flask containing 
500 ml of Terrific Broth (TB) containing 100 µg/mL kanamycin. The cultures were 
incubated at 37°C and 250 rpm for 3-4 h unless the absorbance A590nm = 1. The 
expression of NznB was induced by the addition of 0.8 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and 0.5 mM delta-5-aminolevulinic acid (w/v) as well as 
1mM thiamine. The cultures were incubated further for 30 h, 18°C at 160 rpm. Cells 
were harvested by centrifugation at 5000×g at 4°C for 10 min and the cell pellet was 
stored at –80°C until purification of the protein. 
 
The cell pellet was resuspended in 5% culture volume of lysis buffer (50 mM kPi, 
pH 8.0 containing 200 mM (NH4)2SO4, 20% glycerol, 0.5 mM EDTA, 10 mM beta-
mercaptoethanol and 1mM phenylmethane sulfonyl fluoride (PMSF) and disrupted by 
sonication. The cell lysate was centrifugated (35,000 rpm for 35 min) and filtered (0.2 
µM Millipore filter). The soluble His8-tagged NznB was purified by affinity 
chromatography using Ni-NTA (Qiagen) column and the collected fractions were 
analyzed by SDS-PAGE. The suitable red fractions were pooled and dialyzed at 4°C 
three times using 50 mM Tris, pH 7.4 containing 50 mM kPi, pH 8.0 containing 200 mM 
(NH4)2SO4, 20% glycerol, 0.5 mM EDTA, and 1 mM dithiothreitol (DTT) against a total of 
6 L buffer. 
 
UV–Vis spectra for the purified cytochomes were recorded at room temperature in 
buffer (50 mM Tris-HCl buffer, pH 7.4 containing 5% glycerol) was used for the spectral 
measurements of the oxidized and reduced form. NasB was reduced by the addition of 
a small amount of sodium dithionite. The concentration of the P450s was estimated by 
CO-difference spectra, assuming ε(459–490) = 91 mM−1 cm−1 according to the method 
of Omura and Sato.  
 
Process of crystallization  
Crystallization of NascB-F5053.  
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Single, diffraction quality crystals of the NascB-F5053complexes were grown by sitting 
drop vapor diffusion at 20 °C by mixing 2 µL of 8 mg/mL protein containing 1 mM DKP 
substrate and 0.2% DMSO with 2 µL of a well solution containing 23% PEG 3350, 100 
mM DL-malic acid, 2.5% ethylene glycol. Equimolar concentrations of substrate (0.5 
mM) were used for the NascB-F5053·4·6 complex. Sitting droplets were nucleated after 
4 h from an earlier spontaneous crystallization using a cat whisker. Single crystals grew 
after 48 hours. 8 µL of a cryoprotecting solution containing 10 mM Tris pH 7.5, 2 % 
glycerol, 23% PEG 3350, 100 mM DL-malic acid, 18% ethylene glycol, 1 mM DKP 
substrate, 0.2% DMSO was added directly to the sitting drops and the crystals were 
harvested using nylon loops and vitrified by rapid plunging into liquid nitrogen. NascB-
F5053 crystallized in space group P 1with unit cell dimensions of a = 56.1 Å, b = 56.3 Å, 
c = 58.8 Å, α = 91.1°, β = 92.9°, γ = 100.1° and two chains in the asymmetric unit.  
 
Data collection and processing.  
 
X-ray data were collected at 100 K on beamline 23ID-B at the General Medical 
Sciences and Cancer Institutes Structural Biology Facility at the Advanced Photon 
Source in Argonne, IL, USA. Diffraction data were integrated and scaled using XDS.1 
Data collection statistics are given in Supplementary Table 4-2.  
 
Molecular replacement, model building and refinement.  
 
The structure of NascB-F5053 was solved using Phenix MR-Rosetta.2 This resulted in 
an initial model that could be extended by alternating cycles of manual building in Coot3 
and least-squares refinement with Phenix.4 Final models were validated using 
MolProbity.5  
 
Supplementary Table 4-2. Data Collection Statistics 
  cWP cWP_cWW cWV 
Wavelength (Å) 1.03 1.03 1.03 
Resolution range (Å) 40.83 - 1.49  41.22 - 1.48  34.37  - 1.349 
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(1.54 - 1.49) (1.53 - 1.48) (1.397  - 1.349) 
Space group P 1 P 1 P 21 
Unit cell 
56.12, 56.28, 








56.09 (Å)  
90, 101.74, 90 
(°) 
Total reflections 382537 (31077) 324387 (4806) 496898 (42769) 
Unique reflections 109037 (10046) 94423 (2902) 74183 (7153) 
Multiplicity 3.5 (3.1) 3.4 (1.7) 6.7 (6.0) 
Completeness (%) 94.48 (87.34) 80.96 (24.95) 99.05 (95.79) 
Mean I/sigma(I) 16.78 (2.39) 20.64 (1.81) 16.69 (1.51) 
Wilson B-factor (Å2) 19.96 22.24 18.17 
R-merge 0.039 (0.361) 0.030 (0.287) 0.049 (0.901) 
R-meas 0.046 (0.439) 0.036 (0.398) 0.053 (0.988) 
CC1/2 0.998 (0.85) 0.999 (0.851) 0.999 (0.665) 
  Reflections used in 
refinement 
109025 (10043) 94401 (2902) 74175 (7151) 
R-work 0.168 (0.287) 0.192 (0.333) 0.197 (0.307) 
R-free 0.211 (0.340) 0.234 (0.410) 0.229 (0.386) 
Number of atoms 
(total): 
6989 6995 3550 
macromolecules 6108 6079 3067 
ligands 190 196 85 
solvent 691 720 398 
Protein residues 798 793 396 
RMS(bonds) 0.005 0.007 0.007 
RMS(angles) 0.91 1.23 1.26 





2.79 2.44 2.32 
Ramachandran 
outliers (%) 
0.00 0.00 0.00 
Average B-factor 
(Å2) 
27.51 28.55 25.32 
macromolecules 26.79 28.07 24.59 
ligands 19.50 22.09 17.77 




Molecular Dynamics simulations were performed using the GPU code (pmemd)47 of the 
AMBER 16 package48. Parameters for intermediates and substrates were generated 
within the antechamber module using the general AMBER force field (gaff)49, with partial 
charges set to fit the electrostatic potential generated at the HF/6-31G(d) level by the 
RESP model50. The charges were calculated according to the Merz–Singh– Kollman 
scheme51-52 using the Gaussian 09 package36. Each protein was immersed in a pre-
equilibrated truncated cuboid box with a 10 Å buffer of TIP3P53 water molecules using 
the leap module, resulting in the addition of around 15,000 solvent molecules. The 
systems were neutralized by addition of explicit counter ions (Na+ and Cl−). All 
subsequent calculations were done using the widely tested Stony Brook modification of 
the Amber14 force field (ff14sb)54. A two-stage geometry optimization approach was 
performed. The first stage minimizes the positions of solvent molecules and ions 
imposing positional restraints on the solute by a harmonic potential with a force constant 
of 500 kcal·mol−1·Å−2 and the second stage minimizes all the atoms in the simulation 
cell. The systems were gently heated using six 50 ps steps, incrementing the 
temperature by 50 K for each step (0–300 K) under constant-volume and periodic-
boundary conditions. Water molecules were treated with the SHAKE algorithm such that 
the angle between the hydrogen atoms was kept fixed. Long- range electrostatic effects 
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were modelled using the particle-mesh-Ewald method55. An 8 Å cutoff was applied to 
Lennard–Jones and electrostatic interactions. Harmonic restraints of 10 kcal·mol–1 
were applied to the solute and the Langevin equilibration scheme was used to control 
and equalize the temperature. The time step was kept at 1 fs during the heating stages, 
allowing potential inhomogeneities to self-adjust. Each system was then equilibrated 
without restrains for 2 ns with a 2 fs time step at a constant pressure of 1 atm and 
temperature of 300 K. After the systems were equilibrated in the NPT ensemble, 
subsequent MD simulations were performed for an additional 500 ns under an NVT 
ensemble and periodic-boundary conditions.  
 
Reaction conditions for analytical scale P450 reactions 
The conversion of DKPs by P450s were carried out with the heterologous redox 
electron partners Fdx and FdR from S. olerecea. The in vitro reaction mixture included 
50 mM Tris-HCl, pH 7.4, 10 µM P450, 20 µM Fdx and 3 µM FdR at the end volume of 
250 µL. Without exceeding 1% of the total reaction volume, 1mM of DKP dissolved in 
DMSO was added (in the case of heterodimerization reaction, both substrates were 
added to a final concentration of 1mM). The reaction was initiated by adding NADPH (1 
mM). Two of the control reactions including all the contents except for NADPH or P450 
were used as controls. The reaction was incubated at 30°C for 2 h agitating at 600 rpm 
in a thermoshaker (Multi-thermoshaker, Benchmark). Reactions were quenched by the 
addition of 3 volumes of methanol, and centrifuged at 17,000rpm and directly used for 
HPLC analysis. Reactions were resolved using a linear gradient of 15-75% acetonitrile: 
water (0.1% formic acid) over 16 min (2 mL/min flow rate, 40ºC) on a Phenomenex 
Luna 5µ C-18(2) 100A, 250 × 4.60mm 5 micron column. 
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Figure S4-1. Mass Spectra from first generation probe reaction. Hydroxylated mass as 









































Exact Mass: 336.1319 Exact Mass: 296.1394
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Supplemental Figure 4-2. Mass Spectra from second generation probe reaction. 
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Summary and Future Directions 
 
5.1 Summary 
 This thesis was focused mainly on the identification ad characterization of the 
wild-type activity cytochromes P450 involved in the bacterial biosynthesis of non-
symmetrical diketopiperazine dimers as discussed in Chapters 2-4. In this chapter, I will 
briefly discuss the future direction for the diketopiperazine dimerizing cytochromes 
P450. 
 
5.2 Future Directions 
 
5.2.1 Full substrate scope analysis 
 Diketopiperazines are extremely synthetically accessible, and due to this 
accessibility make for great building blocks. In Chapter 3 we were able to rapidly 
synthesize a handful of monomers and screen them against our 4 cytochromes. 
However, we quickly ran into a problem analyzing these reactions, as the polarity of 
these starting materials and products are heavily overlapped and do not allow for 
quantification of product formed, and in many cases even identification of the number of 
products formed.  
Our goal is to continue to identify more and more diketopiperazine dimerizing 
cytochromes P450 as well as generate variants with new selectivity that we can probe. 
However, as we continuously synthesize diketopiperazine monomers for dimerization 
assays, the number of reactions to be performed and analyzed rapidly grows well 
beyond the capabilities we have at present. For example, if we were to screen 
heterodimerization reactions with 50 diketopiperazine monomers, and run reactions 
where every diketopiperazine is dimerized with every other diketopiperazine, the 
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number of reactions to be run can be calculated using the binomial theorem 
(Equation 1) where n = the total number of diketopiperazines and k = the number of 
monomers in each reaction, which is 2.  !"#$%& !" !"#$%&'() !" !" !"# =  !!! − ! ! !!                    (Equation 1) 
 
Solving this equation we see the number of reactions to be run to screen 50 
diketopiperazine monomers is 1225 for a single cytochrome. This number however 
does not represent the number of possible products formed in these reactions. As we 
saw in many of the homo- and heterodimerization reactions multiple products are 
formed due to the non-symmetrical nature of the dimerization. Again for a given library 
of 50 diketopiperazines, if we assume that there are 4 products formed in each 
heterodimerization reaction of two DKP monomers, A and B (A-A, B-B, A-B, and B-A), 
the number of possible products becomes the square of the number of substrates and 
we have a possible of >2500 unique products. To resolve this issue, our goal is to 
develop a small volume and high-throughput approach to screening reactivity of 
cytochromes as well as development of analytical methods for separations of products. 
To enable this approach we are in preliminary discussions with High-Throughput 
Chemistry facilities at pharmaceutical companies to develop a parallel approach to 
sceening and product identification, and hopefully biological evaluation of the generated 
library of products as well. 
   
5.2.2 Identification of enzymatic mechanism for dimerization selectivity 
 Research from Chapter 4 demonstrated that residues within 5 Å of either 
substrate in the active site are not the key gate-keepers for selectivity in the non-
symmetrical dimerization of diketopiperazine substrates, although some variants were 
unable to be characterized due to instability which is currently still under optimization. 
Given the lack of dramatic changes in reactivity in initial alanine scanning mutagenesis, 
as well as the conformation of the substrates in the active site not representing the 
stereochemistry of the product, we hypothesize the active site of NascB-F5053 must 
undergo dramatic remodeling in order to allow for cyclization and dimerization 
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consistent with the stereochemistry of the product. This remodeling event may involve 
residues outside of this first interacting sphere (>5 Å). To uncover these residues, we 
are currently working towards attaining crystal structures of the other cytochromes from 
this study in complex with their substrates as well as products in hopes of capturing an 
alternative conformation, which may give clues to these gatekeeping residues. We are 
also working with our collaborators in the Houk lab, and performing MD simulations to 
try and identify these residues.  
 The NznB cytochrome generates isomeric dimers relative to NascB, and ideally 
we would be able to acquire a crystal structure of this enzyme to identify residues 
influencing its selectivity. However, the NznB cytochrome is relatively unstable, and 
upon cleavage of of the N-terminal 8X-His tag with TEV protease, the protein 
precipitates. Homologues of NznB from the strains reported in this study (NRRL-F5053 
and NRRL-S1868) are currently under investigation, however their >99% identity may 
result in similar problems with solubility. Curiously, in examining our sequence similarity 
network, we identified another candidate cytochrome with extremely high sequence 
identity to NznB (Figure 5-1). This gene has been codon optimized and is currently 
being synthesized for it’s evaluation as a putative DKP dimerase. 
 
Figure 5-1. Sequence alignment of NznB with putative NznB homologue (WP_030574321.1) from Streptomyces 
aureocirculatus. 
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5.2.3 Recombination and Engineering of NascB 
 As referenced above, active site residues appear to play little to no role in 
selectivity of dimerization. This outcome is not completely unsurprising, as when a 
sequence alignment is performed, assuming active site residues are the same across 
homologues, there are minimal differences in active site residues between NascB-CMB-
MQ030, NascB-5053, NascB-S1868.  
 
Figure 5-2. Sequence alignment of NascB homologues from NRRL-F5053 and NRRL-S1868. 
 
 We hypothesize that regions outside of the active site may be controlling 
selectivity of dimerization, and to identify these regions, homology models of NascB-
CMB-MQ030 and NascB-S1868 were generated with SWISS-MODEL and regions of 
where one homologue had a unique mutation were highlighted (Figure 5-3). To identify 
how NascB-CMB-MQ030 can selectively generate (–)-naseseazine C, and how NascB-
S1868 can exclusively generate (–)-aspergilazine, while NascB-F5053 generates a 
mixture of both, we propose to graft these regions of low-no conservation of NascB-
S1868 and NascB-CMB-MQ030 onto NascB-F5053 and assay the products of these 
chimaeras. Along with using the homology model to identify key regions for 
chimaeragenesis, we also propose to use SCHEMA1 and other computational tools for 




Figure 5-3. Unique variations from each NascB variant are highlighted as colored spheres on the NascB-F5053 
structure. Blue = NascB-F5053, Purple = NascB-S1868, Pink = NascB-CMB-MQ030. 
 
5.3.4 Directed Evolution of NascB-F5053 
 The original goal of this thesis was to not only discover the dimerizing 
cytochromes, but to engineer them into synthetically useful designer biocatalysts to 
access any connectivity and stereochemistry of dimer on demand in a catalyst 
controlled fashion such that a single monomer could be used to construct a variety of 
dimers. However, as previously mentioned, active site residues are not playing an 
obvious role in dimerization selectivity, and as such selecting residues for mutagenesis 
cannot easily be performed rationally. It is well precedented in directed evolution 
campaigns to engineer new selectivity into enzymes, that residues well outside of the 
active site are those that have undergone mutagenesis in variants with new selectivity. 
Given that our enzyme active site does not appear to be influencing selectivity anyway, 
we have begun investigation into development of a high-throughput platform for directed 




Figure 5-4. Proposed biocatalyst controlled dimerization of a single monomer to a variety of known and natural 
product dimers. 
 
Indole fuctionalizing enzymes have been engineered with new selectivity via 
directed evolution, with a key example being C6-indole halogenase ,RebH. Lewis et. al. 
utilized directed evolution to engineer RebH with new selectivity by utilizing a deuterium 
incorporation approach allowing for rapid screening via mass spectroscopy alleviating 
the need for separation of similar compounds.2-6 
 
Figure 5-5. Lewis et. al. deuterium labeling strategy for directed evolution of RebH. 
 
 We considered using this approach, as we could incorporate deuterium into our 
diketopiperazines using similar methodology, however in examining some of the target 
products we saw that the protons that would be lost in the course of the reaction would 
be those exchangeable with solvent and therefore would not be detected/could not be 
screened for using this approach. Looking back at our initial data from Chapter 2, we 
saw that fluorination at the position of dimerization completely stopped reactivity, while 
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conversion. As such we decided to adopt a fluorine incorporation strategy, wherein the 
position where the carbon-carbon bond would be natively formed would be blocked by a 
fluorine, and any variant that can form any other bond would generate a dimer (Figure 
5-6). 
 
Figure 5-6. Strategy for fluorine incorporated directed evolution strategy for NascB-F5053. 
 
 This strategy would allow not only detection of variants with new selectivity, but 
also through polyfluorination of the arene ring we would be able to detect formation of 
dimers undetectable through deuterium incorporation such as C3-C3’ linked 
symmetrical dimers (such as dibrevianamide F), as well as C3-N1’ linked dimers (Figure 
5-7). This also enables a more facile analysis, as rather than discerning a difference in a 
single AMU as you would for deuterium labeling, the readout for this assay would be 
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